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ABSTRACT 
 
Autophagy is a cellular process to sequester cytoplasmic components for delivery 
to lysosomes for subsequent degradation, and plays important roles in aging and aging-
associated pathogenesis. MAP1S is a ubiquitously distributed autophagy activator, which 
directly binds to the autophagosome marker LC3, accelerates autophagy initiation and 
degradation. Elucidating the mechanism of MAP1S-mediated autophagy can generate 
insights to control aging and aging-associated diseases. We discover that the acetylation 
of MAP1S maintains the stability of MAP1S protein and promotes autophagy. MAP1S 
interacts with HDAC4 via an HDAC4-binding domain (HBD). HDAC4 destabilizes 
MAP1S via deacetylation and suppresses autophagic flux.  
Huntington’s disease is a fatal progressive neurodegenerative disorder caused by 
the accumulation of aggregation-prone mutant Huntingtin protein (mHTT). Utilizing cell 
line stably expressing GFP-mHTT, we demonstrate that an overexpression of HDAC4 
causes accumulation of mHTT aggregates by inhibiting MAP1S-mediated autophagy. 
Either suppression of HDAC4 or overexpression of HBD promotes the stability of 
MAP1S, and enhances MAP1S-regulated autophagic clearance of mHTT aggregates. 
This reveals a new potential strategy to treat Huntington’s disease by interrupting 
HDAC4-MAP1S interaction. 
Spermidine is a polyamine that activates autophagy and enhances longevity in 
some model systems. MAP1S-mediated autophagy helps mice maintain their lifespans 
and suppresses diethylnitrosamine-induced hepatocellular carcinomas. Thus, we 
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hypothesize that spermidine regulates MAP1S-mediated autophagy to prolong lifespans 
and suppress hepatocarcinogenesis. Our results indicate that spermidine activates 
autophagy by depleting cytosolic HDAC4 to reduce HDAC4-MAP1S interaction, and 
enhance the acetylation of MAP1S. Wild-type mice drinking spermidine-containing 
water have higher levels of MAP1S and autophagy activity, and extended lifespans, 
compared to wild-type mice drinking water; whereas MAP1S-/- mice drinking spermidine 
have no significant increase in autophagy level and medium survival time, compared to 
MAP1S-/- mice drinking water. Utilizing diethylnitrosamine-induced hepatocellular 
carcinoma mouse model, we find that spermidine enhances MAP1S to accelerate 
autophagic flux and suppress hepatocarcinogenesis in a MAP1S-dependent manner. 
In sum, we uncover that HDAC4 deacetylates MAP1S, reduces the stability of 
MAP1S protein and impairs MAP1S-mediated autophagy. Blocking the association of 
MAP1S with HDAC4 leads to activation of MAP1S-mediated autophagy and 
suppression of aging and aging-associated diseases. 
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NOMENCLATURE 
 
AGERA                      Agarose Gel Electrophoresis for Resolving Aggregates 
AFB                            Aflatoxin B1 
ARLD                         Alcohol-related Liver Disease 
ATG                            Autophagy-related  
BAF                            Balifomycin A1 
Bcl-2/xL                      B-cell CLL/lymphoma 2 or xL 
BSA                             Bovine Serum Albumin 
CCl4                            Carbon Tetrachloride 
ccRCC                         Clear Cell Renal Cell Carcinoma 
CE                               Cytoplasmic Extract 
CHX                            Cycloheximide 
CR                               Calorie Restriction 
CT                               Comparative Threshold 
DAB                            3, 3’-Diaminobenzidine 
DEN                            Diethylnitrosamine 
DHE                            Dihydroethidium 
DMEM                        Dulbecco’s Modified Eagle Medium 
DMSO                         Dimethyl Sulfoxide 
DSB                             Double-strand Breaks 
EBSS                           Earle’s Balanced Salt Solution 
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EMEM                        Eagle's Minimum Essential Medium  
FBS                             Fetal Bovine Serum 
FL                                Full Length 
GFP Green Fluorescent Protein 
GST                             Glutathione S-transferase 
HAT                            Histone Acetyltransferase 
HBD                            HDAC4-bind Domain           
HBSS                          Hanks' Balanced Salt Solution 
HBV                            Hepatitis B Virus 
HC                               Heavy Chain 
HCC                            Hepatocellular Carcinoma 
HCV                            Hepatitis C Virus 
HD Huntington’s Disease 
HDAC                         Histone Deacetylase 
HDAC4 Histone Deacetylase 4 
HDACi                        Histone Deacetylase Inhibitor 
HEK                            Human Embryonic Kidney 
HIF-1α                         Hypoxia-inducible Factor-1α 
HRP                             Horseradish Peroxidase 
HTT Huntingtin 
H&E                            Hematoxylin and Eosin    
ITS-G                          Insulin-Transferrin-Selenium 
  ix 
IHC                             Immunohistochemistry 
LAMP2                       Lysosome-associated Membrane Protein 2 
LC                               Light Chain 
LC3                             Microtubule-associated Protein 1A/B Light Chain 3 
LRPPRC                      Leucine-rich Pentatricopeptide Repeat Containing 
MAP1A                       Microtubule-associated Protein 1A 
MAP1B                       Microtubule-associated Protein 1B 
MAP1S Microtubule-associated Protein 1 Small Form 
MAGD                        Mitochondrial Aggregation and Genomic Destruction 
MEF                            Mouse Embryonic Fibroblast 
MEF2                          Myocyte Enhancer Factor-2 
MEKK2                      Mitogen-activated Protein Kinase Kinase Kinase 2 
MT                              Microtubule 
mHTT Mutant Huntingtin 
N2α                             Neuro-2α 
NAD                           Nicotinamide Adenine Dinucleotide 
NAFLD                       Non-alcoholic Fatty Liver Disease 
NAM                           Nicotinamide 
NASH                         Non-alcoholic Steatohepatitis 
NE                               Nuclear Extract 
NMDAR                     N-methyl-D-aspartate Receptor 
P27                              Cyclin-dependent Kinase Inhibitor 1B 
  x 
PBS                             Phosphate-buffered Saline 
PCa                             Prostate Adenocarcinoma 
PE                               Phosphatidylethanolamine 
PI3K                            Phosphoatidylinositol-3-kinase 
PI3P                            Phosphatidylinositol-3-phosphate 
PMSF                          Phenylmethanesulfonyl Fluoride 
PolyQ                          Polyglutamine       
PP2A                           Protein Phosphatase-2A 
PVDF                          Polyvinylidene Difluoride 
RASSF1A                   Ras-association Domain Family 1 Isoform A 
RFP                             Red Fluorescent Protein 
ROS                             Reactive Oxygen Species 
Runx2                          Runt-related Transcription Factor 2 
SC                               Short Chain 
SDS                             Sodium Dodecyl Sulfate 
STAT1                        Signal Transducer and Activator of Transcription 1 
TBST                          Tris-buffered Saline with Tween-20 
TOR                            Target of Rapamycin 




TABLE OF CONTENTS 
Page 
ABSTRACT ..............................................................................................................       ii 
DEDICATION ..........................................................................................................        iv 
ACKNOWLEDGEMENTS ......................................................................................       v 
NOMENCLATURE ..................................................................................................       vii 
TABLE OF CONTENTS ..........................................................................................        xi 
LIST OF FIGURES ...................................................................................................     xiii 
LIST OF TABLES ....................................................................................................       xv 
CHAPTER I INTRODUCTION ...............................................................................    1 
CHAPTER II MAP1S IS NEGATIVELY REGULATED BY HDAC4 VIA 
DEACETYLATION ..................................................................................................       10 
Introduction .....................................................................................       10 
Materials and Methods ....................................................................       13 
Results .............................................................................................       23 
Discussion .......................................................................................       37 
CHAPTER III ACETYLATED MAP1S ACCELERATES AUTOPHAGIC 
CLEARANCE OF MUTANT HUNTINGTIN AGGREGATES .............................       40 
Introduction .....................................................................................       40 
Materials and Methods ....................................................................       43 
Results .............................................................................................       49 
Discussion .......................................................................................       64 
CHAPTER IV SPERMIDINE ACTIVATES MAP1S-MEDIATED AUTOPHAGY 
TO PROLONG LIFESPANS AND SUPPRESS DIETHYLNITROSAMINE  
-INDUCED HEPATOCARCINOGENESIS ...........................................................       68 
Introduction ....................................................................................       68 
Materials and Methods ...................................................................       73 
xii 
Page 
Results ............................................................................................       81 
Discussion ......................................................................................     105 
CHAPTER V CONCLUSIONS ...............................................................................     109 
REFERENCES .........................................................................................................     113 
xiii 
LIST OF FIGURES 
Page   
Figure 1.    Depletion of MAP1S Suppresses Autophagic Flux. ................................       24	
Figure 2.    HDAC Inhibitor Apicidin Enhances the Acetylation of MAP1S 
and Promotes Autophagic Flux. ..............................................................      26	
Figure 3.    HDAC4 Interacts with MAP1S. ..............................................................      27	
Figure 4.    HDAC4 Negatively Regulates MAP1S. ..................................................      29	
Figure 5.    HDAC4 Destabilizes MAP1S via Deacetylation. ....................................      30	
Figure 6.    HDAC4-induced Deacetylation of MAP1S Depends on HDAC4 
Catalytic Activity.  ..................................................................................      32	
Figure 7.    HDAC4 Inhibits Autophagic Flux Indicated by Immunoblot 
Analyses. .................................................................................................      33	
Figure 8.    HDAC4 Inhibits Autophagic Flux Indicated by Fluorescence and 
Electron Microscopy. ..............................................................................      34	
Figure 9.    HDAC4 Inhibits Autophagic Flux through MAP1S. ...............................      36	
Figure 10.   HDAC4 Induces Mutant Huntingtin Aggregation Indicated by 
Fluorescence Microscopy. .......................................................................      49	
Figure 11.   HDAC4 Induces Mutant Huntingtin Aggregation Indicated by 
Immunoblot Analyses. .............................................................................      51	
Figure 12.   Mutant Huntingtin Is Degraded in Lysosomes. ......................................      52	
Figure 13.   HDAC4 Inhibits MAP1S-mediated Autophagic Clearance of 
Mutant Huntingtin Aggregates. ...............................................................      54	
Figure 14.   MAP1S Interacts with HDAC4 via an HDAC4-binding Domain 
(HBD) in the Overlapping Region between the Heavy Chain (HC) 
and Short Chain (SC) of MAP1S. ..........................................................       56	
Figure 15.   Overexpression of HBD Interrupts HDAC4-MAP1S Interaction, 
Activates MAP1S-mediated Autophagy. ................................................      59	
xiv 
Page 
Figure 16.   Overexpression of HBD Alleviates HDAC4-induced Mutant 
Huntingtin Aggregation. ..........................................................................      62	
Figure 17.   Potential Mechanism of HDAC4 in MAP1S-mediated 
Autophagic Clearance of Mutant Huntingtin Aggregates. ......................      63	
Figure 18.   Spermidine Accelerates Autophagic Flux. .............................................      82	
Figure 19.   Spermidine-induced Autophagy Depends on MAP1S. ..........................      83	
Figure 20.   Spermidine Enhances the Acetylation and Stability of MAP1S 
Protein through HDAC4. .........................................................................      85	
Figure 21.   Mutation of MAP1S Lysine 520 Residue Inhibits Autophagy. ..............      87	
Figure 22.   Lysine 520 Residue of MAP1S Is Critical in Spermidine-
induced Autophagy. .................................................................................      90	
Figure 23.   Spermidine Enhances Levels of HDAC4 Protein. ..................................      92	
Figure 24.   Spermidine Suppresses Cytosolic HDAC4. ............................................      93	
Figure 25.   Spermidine Dephosphorylates HDAC4 and Induces the 
Dissociation of HDAC4 from 14-3-3. .....................................................      95	
Figure 26.   Spermidine Interrupts the Association of HDAC4 with MAP1S. ..........      96	
Figure 27.   Feeding Mice with Spermidine for One Month Enhances Levels 
of MAP1S Protein and Autophagy Activity. ...........................................      98	
Figure 28.   Feeding Mice with Spermidine for Eighteen Months Enhances 
MAP1S-mediated Autophagy to Suppress Oxidative Stress. .................    100	
Figure 29.   Spermidine-induced Lifespan Extension Is MAP1S-dependent. ...........    101	
Figure 30.   Spermidine Suppresses Diethylnitrosamine-induced 
Hepatocellular Carcinomas in the Presence of MAP1S. .........................    103	
Figure 31.   Spermidine Enhances Levels of MAP1S Protein to Suppress 
Genomic Instability during Hepatocarcinogenesis. .................................    103	
Figure 32.   Proposed Model of Activation of MAP1S-mediated Autophagy 
by Inhibiting HDAC4 in Suppressing Aging and Aging-
associated Diseases. .................................................................................    110 
xv 
LIST OF TABLES 
Page 
Table 1.    Primers Used for Verification of Mouse Genotypes. ................................      13	
Table 2.    DNA Oligos for gRNAs Targeting Human MAP1S. ................................      16	
Table 3.    Catalog Numbers and Dilutions of Primary Antibodies-I. ........................      18	
Table 4.    Catalog Numbers and Dilutions of Primary Antibodies-II. ......................      77	
1 
CHAPTER I  
INTRODUCTION 
Aging is the time-dependent process of functional loss that affects most 
organisms, and accounts for the primary risk factor for various human diseases (1). The 
incidence of chronic diseases, such as neurodegenerative diseases, metabolic disorders, 
sarcopenia, and cancers, increases dramatically in the aged population. Though global 
life expectancy has increased in the past fifteen years, the number of deaths increases as 
well over the same interval (2). Particularly, the death rate increases significantly in the 
group of people older than age 80. Therefore, extending healthy lifespans become a 
major challenge in medical sciences. 
Aging is mainly resulted from the accumulation of cellular damage. Several 
cellular and molecular hallmarks of aging have been identified, including the primary 
hallmarks of genomic instability and proteostasis deficiency (3). Importantly, recent 
evidence shows that weak autophagy activity and high levels of oxidative stress are 
correlated with short lifespans (4). Thus, activation of autophagy to alleviate cellular 
oxidative stress is one of the most efficient approaches to prevent aging and aging-
associated diseases. 
Autophagy is a cellular self-degradation process that was first observed in the 
1960s (5), and has been identified as the primary machinery to remove misfolded 
proteins, aggresomes, and dysfunctional organelles. The process of autophagy begins 
with the formation of cytosolic double-membrane vesicles, so-called autophagosomes, 
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containing sequestered substrates. Autophagosomes are sequentially transported along 
acetylated microtubules to fuse with lysosomes to form autolysosomes, in which 
autophagic substrates are degraded (6). The whole process of autophagy can be divided 
into several sequential steps, including autophagy induction, autophagosome formation, 
autophagosome-lysosome fusion, and degradation (7).  
In the recent decades, significant progress has been made in understanding the 
molecular mechanisms of autophagy. A number of autophagy-related (ATG) gene-
encoded proteins have been shown to be involved in autophagy regulation. As autophagy 
functions in a step-dependent manner, these ATG proteins are generally classified into 
three groups based on their functions at each step. The target of rapamycin (TOR) kinase 
and its effectors (ATG1, ATG2, ATG9, ATG13, ATG17, and ATG18) coordinately 
regulate autophagy induction. As the key component in autophagy regulation, TOR 
activity is regulated in response to nutrients availability, growth factor signaling, and 
cellular stress (8). TOR interacts with and inactivates ATG1 via direct phosphorylation. 
Under the condition of starvation or stress that induces autophagy, TOR activity is 
inhibited, which leads to ATG1 dissociated from TOR and dephosphorylation-induced 
activation of ATG1. Activated ATG1 further phosphorylates ATG13 and triggers 
downstream effectors for autophagy initiation. Class III phosphoatidylinositol-3-kinase 
(PI3K) complex (ATG6, ATG14, and VPS34) is the critical regulator of autophagosome 
nucleation. ATG6 interacts with class III PI3K (VPS34) to increase VPS34 kinase 
activity for generating phosphatidylinositol-3-phosphate (PI3P), an essential component 
that forms membrane and recruits proteins during autophagosome nucleation (9). Two 
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ubiquitin-like protein conjugation systems regulate the extension and completion of 
autophagosomes: the ATG12 conjugation system (ATG5, ATG12, and ATG16), and the 
LC3 (microtubule-associated protein 1 light chain 3, the mammalian homolog of ATG8) 
lipidation system (ATG3, ATG7, and LC3) (10). ATG12, an ubiquitin-like protein, can 
be firstly activated by ATG7 as an ubiquitin-activating enzyme E1-like protein, and then 
mediated by ATG10 as an ubiquitin-conjugating enzyme E2-like protein to form the 
ATG5-ATG12 conjugate. ATG16 interacts with ATG5-ATG12 conjugate to form a 
complex facilitating LC3 lipidation (11,12). In the LC3 lipidation system, LC3 precursor 
is firstly cleaved by ATG4 to remove its C-terminus to produce the cytosolic LC3-I. 
Mediated by the E1-like enzyme ATG7 and E2-like enzyme ATG3, LC3-I is conjugated 
to phosphatidyl-ethanolamine (PE) to generate membrane-associated LC3-II, which is 
recruited to both sides of the phagophore membrane. Once autophagosome formation is 
completed, ATG4 cleaves PE from LC3-II that localizes on the outer autophagosomal 
membrane, to release LC3 back to the cytosol for recycling (13).  
LC3 is a commonly used marker for autophagy (14). The conversion from LC3-I 
to LC3-II indicates autophagosomal formation and the degradation of LC3-II indicates 
autolysosomal degradation. Either autophagy initiation or autophagy degradation affects 
levels of LC3-I and LC3-II. To perform an accurate measurement for autophagy level, 
lysosome inhibitors are utilized to block the degradation of autolysosomes, which leads 
to accumulation of LC3-II. With application of lysosome inhibitor, such as bafilomycin 
A1 (BAF), chloroquine, and ammonium chloride, levels of accumulated LC3-II can 
precisely represent autophagy activity (14). 
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Autophagy is the most important mechanism that regulates aging and aging-
associated pathologies. Autophagy facilitates the removal of aggresomes and damaged 
organelles, reduces oxidative stress that further leads to cellular damage and genomic 
instability (15). The accumulation of aggresomes and dysfunctional organelles due to 
autophagy deficiency results in oxidative stress-induced toxicity in the cytoplasm which 
directly impacts on aging (4). In addition, autophagy serves as the primary mechanism 
that maintains homeostasis during nutrient fluctuation. Multiple nutrient-sensing 
signaling pathways, such as LKB1-AMPK-TOR signaling pathway, regulate autophagy 
to prolong lifespans under nutrient stress (16,17). The incidence of aging-associated 
pathologies increases with accumulation of cellular damage resulted from low levels of 
autophagy activity. Therefore, induction of autophagy is one of the most promising 
strategies to extend healthy lifespans and suppress aging-associated diseases, such as 
neurodegenerative disorders and cancers.   
Neurodegenerative disorders are caused by progressive loss of neurons, due to 
the accumulation of toxic oligomeric and polymeric aggregates formed by altered 
proteins (18). As one of the most common neurodegenerative diseases, Huntington’s 
disease (HD) occurs as a result of an autosomal dominant mutation with expansion of 
more than 36 trinucleotide CAG repeats which codes for polyglutamine (ployQ) in exon 
1 of the huntingtin gene encoding Huntingtin protein (HTT) (19,20). PolyQ expansions 
longer than 36 residues render HTT prone to aggregate into insoluble inclusion bodies 
which are toxic to cells and promote neuronal death eventually (18). Striatum, primarily 
mediating cognition and motor function, is the most affected area in the brain by the 
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formation of mutant Huntingtin (mHTT) aggregates. Thus, HD patients suffer 
progressive cognitive impairment, uncontrolled movement ability. The incidence of HD 
mainly occurs in North America, Europe and Australia with an overall prevalence of 5.7 
per 100,000 (21), and an increasing rate of 15-20% per decade (22). HD leads to an 
average age of onset around age 35-40, and ultimately death within 10-20 years after 
diagnosis (23).  
At present, there are no treatments available to alter the course of HD. Research 
on curing HD mainly focuses on neuronal replacement, neuronal survival improvement, 
reduction of mHTT production and promotion of mHTT degradation. Autophagy is an 
important biological process that controls and executes the turnover of abnormally 
aggregated proteins, including mHTT (24). Therefore, up-regulating autophagy activity 
or preventing autophagy dysfunction may be a potential therapeutics for HD (23).  
Cancer is a leading cause of death worldwide with increasing incidence 
associated with the aging of population. Among all the cancers, liver cancer is the 
second leading cause of cancer death (25). In the United States, both liver cancer cases 
and deaths have increased by more than twice during the past twenty-five years (26,27). 
Hepatocellular carcinoma (HCC) is the most common type of liver cancer, caused by 
long-term damage in the liver (28). Most HCC develops with a clinical history of liver 
cirrhosis, a chronic hepatic disease with excessive accumulation of extracellular matrix 
deposition, induced by long-term injuries, such as viral infection (Hepatitis B, HBV and 
Hepatitis C, HCV), alcohol-related liver disease (ARLD), non-alcoholic fatty liver 
disease (NAFLD) or non-alcoholic steatohepatitis (NASH) (29). Currently, most HCC 
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patients are diagnosed in the age of 50 or later with no effective treatment available; only 
small portions of HCC patients are diagnosed early enough that may be treated by 
surgical resection or liver transplantation (30). The prognosis of HCC is very 
unfavorable. In the United States, the one-year survival is less than 50%, and the five-
year survival is only 10% (31). Thus, effective treatments and prevention approaches for 
HCC are in urgent need.  
As the major pathway for removing dysfunctional organelles and misfolded 
proteins, autophagy is implicated in tumor suppression. Autophagy activity is elevated 
immediately in response to cellular stress. Activated autophagy removes aggresomes and 
damaged organelles that trigger DNA double-strand breaks (DSB) and genomic 
instability. Autophagy deficiency leads to an unstable genome and ultimately 
tumorigenesis. In addition to tumor initiation, tumor development induces autophagy to 
suppress genomic instability in tumor foci (15). Multiple animal studies confirm that 
autophagy deficiency promotes hepatocellular carcinogenesis (32,33). Clinical evidence 
also suggests that low levels of autophagy activity are associated with poor prognosis of 
cancer patients (34-36). Therefore, elevating autophagy activity may be helpful to 
prevent or treat HCC. 
Microtubule-associated protein 1 small form (MAP1S) is a novel microtubule-
associated autophagy activator. It was first cloned from a liver cDNA library and named 
as C19ORF5 based on the chromosomal location of its encoding gene (37). MAP1S is a 
widely distributed homologue of MAP1A and MAP1B (38,39). Similar to other 
members in the MAP1 family, MAP1S full length (FL) is synthesized as a precursor and 
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cleaved into multiple isoforms, including heavy chain (HC), short chain (SC), and light 
chain (LC) (40). MAP1S SC binds to microtubule and causes mitochondrial aggregation 
and genomic destruction (MAGD) (38); FL, HC and SC interact with mammalian 
autophagy marker microtubule-associated protein 1A/B light chain 3 (LC3) (41). All the 
MAP1S isoforms coordinately regulate autophagy initiation and autophagosome 
maturation. Depletion of MAP1S reduces the protein levels of B-cell CLL/lymphoma 2 
or xL (Bcl-2/xL) and cyclin-dependent kinase inhibitor 1B (P27), which further results 
in decreased levels of autophagy initiation (41,42). As an autophagy regulator, MAP1S 
suppresses aging and tumorigenesis. MAP1S deficient mice have shortened lifespans (4) 
and develop more and larger foci of HCC after exposed to diethylnitrosamine (DEN) 
(33). In addition, MAP1S has been identified as a novel prognostic marker of patients 
suffering from prostate adenocarcinomas (PCa) (35) and clear cell renal carcinomas 
(ccRCC) (36). Cancer patients with low levels of MAP1S have shortened survival span. 
Thus, MAP1S is a potential target to induce autophagy to suppress aging and aging-
associated diseases. A better understanding of the molecular detail of MAP1S can 
generate more insights on MAP1S-mediated autophagy and contribute to drug discovery 
of autophagy inducer in future. 
Histone deacetylases (HDACs) are classes of enzymes that can remove acetyl 
groups from lysine on either histones or non-histone proteins (43). Mammalian HDACs 
are classified into four groups based on the homology to yeast proteins. All HDACs have 
one or two zinc-containing catalytic domains except Class III HDACs. Class I HDACs 
that are mainly localized in nucleus include HDAC1, HDAC2, HDAC3, and HDAC8. 
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Class II HDACs can be further divided into two subgroups. Class IIa HDACs, consisted 
of HDAC4, HDAC5, HDAC7 and HDAC9, have a binding domain for myocyte 
enhancer factor-2 (MEF2) and conserved phosphorylation sites that are important for the 
interaction with 14-3-3 protein for nucleus/cytoplasm trafficking. Class IIb HDACs 
include HDAC6 and HDAC10, and mainly function in cytoplasm. Class III HDACs are 
the sirtuins family of deacetylases that require nicotinamide adenine dinucleotide (NAD) 
for deacetylase activity. HDAC11 is classified individually into Class IV, due to the 
conserved residues shared by both Class I and Class II HDACs in the catalytic domain 
(44).  
Histone deacetylation leads to condensed nucleosomes that block the binding of 
transcription factors to the targeted genes. Thus, deacetylation of histones represses gene 
expression through epigenetic regulation (45). Acetylation and deacetylation process in 
non-histone proteins is one of the major post-translational modifications that regulates 
protein stability, activity, cellular localization, and binding affinity (46). Recently, 
protein acetylation and deacetylation process has been identified as an important 
mechanism involved in autophagy regulation (17). Reduction in levels of 
acetyltransferases or acetyl-CoA can stimulate autophagy and prolong lifespans (47). In 
addition, activation of sirtuins promotes autophagy-dependent lifespan extension (48). 
Interestingly, histone deacetylase inhibitors (HDACi), the novel treatments for cancers, 
are reported as autophagy inducers (49,50), though the mechanism is still unclear. 
Therefore, further study is necessary to understand acetylation and deacetylation 
regulation in individual proteins involved in autophagy, such as MAP1S. 
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As autophagy is critical in extending lifespans and suppressing aging-associated 
diseases, pharmacologic intervention that induces autophagy is a novel direction for drug 
development. Spermidine has been identified as an autophagy inducer and longevity 
enhancer recently (51). It is a polyamine synthesized from putrescine and serves as a 
precursor of spermine. The name of spermidine is given for its high concentration in 
sperm, in addition to its abundance in citrus fruits, soybeans, and wheat germ (52). 
Studies have shown that spermidine extends the lifespans of yeast, nematodes, and flies 
in an autophagy-dependent fashion (51). The mechanism by which spermidine induces 
autophagy is suggested to be a combination of transcription-dependent and independent 
regulatory events but still not well understood (53). Unlike canonical autophagy inducers 
that have severe immunosuppressive effects, such as rapamycin, spermidine is a natural 
compound in food and should have fewer side effects. Besides, spermidine is a small 
molecule that can easily enter cells to execute its biological function. Thus, spermidine is 
a potential treatment to induce autophagy. At present, the impact of spermidine-induced 
lifespan extension has not been studied on mammals. The role of spermidine in cancer 
prevention and suppression is worth studying as well. Meanwhile, determining the 
mechanism of how spermidine modulates autophagy can contribute to the development 
of novel autophagy inducers for improving healthy lifespans. 
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CHAPTER II  
MAP1S IS NEGATIVELY REGULATED BY HDAC4 VIA DEACETYLATION*1 
Introduction 
Microtubule-associated protein 1 small form (MAP1S, previously called 
C19ORF5) associates with microtubules (38,54). Like its neuronal specific sequence 
homologues microtubule-associated protein 1A and 1B (MAP1A and MAP1B), widely 
distributed MAP1S interacts with the autophagosome-associated light chain 3 of 
MAP1A/B (LC3), and bridges autophagic components with microtubules to affect 
autophagosomal biogenesis and degradation (41).  
B-cell CLL/lymphoma 2 (Bcl-2) is originally characterized as an anti-apoptotic 
protein, and also exhibits opposite roles in autophagy. By directly interacting with 
Beclin 1, the mammalian homolog of ATG6, Bcl-2 prevents the association of Beclin1 
with class III PI3K and inhibits Beclin 1-dependent autophagy. On the other hand, Bcl-2 
elevates levels of cyclin-dependent kinase inhibitor 1B (P27) that enhances ATG5 level 
to activate autophagy through a Beclin 1-independent pathway (42,55,56). Ablation of 
the Map1s gene in mice results in reduction in levels of Bcl-2 and P27, suggesting 
MAP1S enhances autophagy initiation by sustaining levels of Bcl-2 and P27 (41).  
*Part of this chapter is reprinted with permission from “Blocking the Association of
HDAC4 with MAP1S Accelerates Autophagy Clearance of Mutant Huntingtin” by Yue, 
F., Li, W., Zou, J., Chen, Q., Xu, G., Huang, H., Xu, Z., Zhang, S., Gallinari, P., Wang, 
F., McKeehan, W. L., and Liu, L, 2015, Aging 7, 839-853, Copyright [2015] by Fei Yue. 
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In addition, MAP1S may regulate autophagy through one of its interactive 
proteins. Leucine-rich pentatricopeptide repeat containing (LRPPRC) is a mitochondrial 
inner membrane protein that associates with MAP1S (38,57) and has been suggested to 
play a suppressive role in autophagy initiation. LRPPRC interacts with Beclin 1 and Bcl-
2 simultaneously to form a ternary complex to maintain the stability of Bcl-2, and further 
inhibits autophagy initiation (58). Therefore, MAP1S may bind with LRPPRC and 
participate in regulating the association between Beclin 1 and Bcl-2 complex to affect 
autophagy activity. 
Both the direct function of MAP1S association with microtubules and 
autophagosome-associated LC3, and indirect positive impact of MAP1S on autophagy 
initiation through Bcl-2 and P27 enhance the overall rate of autophagic flux (20,41). 
However, the upstream regulators of MAP1S have not been identified. Elucidating the 
mechanism by which MAP1S is regulated can generate new knowledge in autophagy 
regulation. 
Histone deacetylases 4 (HDAC4) belongs to the Class II subgroup a of the 
HDACs family (44), which can shuttle between the nucleus and cytoplasm. In the 
nucleus, HDAC4 binds with the myocyte enhancer factor-2 (MEF2) through a conserved 
MEF2 binding domain in the N-terminal of HDAC4 and represses MEF2 transcriptional 
activation (59). In addition, emerging evidence indicates that HDAC4 interacts with and 
regulates a variety of non-histone proteins, such as runt-related transcription factor 2 
(Runx2), hypoxia-inducible factor-1α (HIF-1α), signal transducer and activator of 
transcription 1(STAT1), and mitogen-activated protein kinase kinase kinase 2 (MEKK2), 
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via direct deacetylation (60-63). Though HDAC4 plays global roles in the regulation of 
gene transcription and further controls cell growth, survival and proliferation (64), its 
impact on autophagy is poorly understood.  
To characterize the molecular detail of MAP1S protein and identify the upstream 
regulator of MAP1S, we first focus on the post-translational modification of MAP1S 
protein. In addition to the fact that acetylation and deacetylation process is an important 
mechanism to regulate protein function and stability, a yeast two-hybrid screen result 
suggests a potential interaction between HDAC4 and MAP1S (65), which encourages us 
to investigate whether HDAC4 regulates MAP1S via deacetylation and further affects 
autophagy activity through MAP1S.  
Herein we show that depletion of MAP1S leads to suppression of autophagic flux 
and confirm MAP1S as an autophagy activator in multiple cell lines. Importantly, we 
discover that MAP1S can interact with HDAC4, but have no impact on the protein level 
of HDAC4. However, HDAC4 decreases the stability of MAP1S protein by catalyzing 
deacetylation of acetylated MAP1S and inhibits autophagic flux through MAP1S (20).  
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Materials and Methods 
Animals 
Animal protocols were approved by the Institutional Animal Care and Use 
Committee (IACUC), Institute of Biosciences and Technology, Texas A&M Health 
Science Center. All animals received human care according to the criteria outlined in the 
‘Guide for the Care and Use of Laboratory Animals’ prepared by the National Academy 
of Sciences and published by the National Institutes of Health (NIH publication 86-23 
revised 1985). C57BL/6 wild-type and MAP1S-/- mice were bred and genotyped as 
previously described (41). Primers used for verification of mouse genotypes are listed in 
the Table 1.  
Table 1. Primers Used for Verification of Mouse Genotypes. 
Cell Culture 
Most cell lines, including HeLa, HepG2, human embryonic kidney (HEK)-293T, 
COS-7 cells, HeLa cells stably expressing ERFP-LC3 (HeLa-RFP-LC3), and mouse 
embryonic fibroblast (MEF) cells that were established as described (41), were cultured 
in the Dulbecco’s Modified Eagle Medium (DMEM) (GenDEPOT, #CM001) containing  
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10% Fetal Bovine Serum (FBS) (Invitrogen, #26140) and antibiotics (Thermo Scientific, 
#SV30010). Primary mouse hepatocytes were grown in William’s E culture media 
(Sigma, #W4125) with 10% FBS, Insulin-Transferrin-Selenium (ITS-G) (Invitrogen, 
#51300-044), antibiotics and 100 nM dexamethasone (Sigma, D4902). Phosphate-
buffered saline (PBS), pH 7.4 and 0.25% trypsin (Thermo Scientific, #SV30031.01) 
were used for subculture.  
 
Cell Transfection 
Cell lines used for transfection included HeLa, HepG2, HEK-293T, COS-7 cells, 
HeLa-RFP-LC3 cells, or MEF cells. For transient knockdown experiments, cells were 
cultured at 30% confluence on the cell culture plates or coverslips and transfected with 
negative control siRNA or specific siRNA by Oligofectamine (Invitrogen, #12252-011) 
according to the manufacturer’s recommended instruction. For transient overexpression 
experiments in HeLa, HepG2, COS-7 cells, HeLa-RFP-LC3 cells, or MEF cells, cells 
were cultured at 70% confluence on the cell culture plates or coverslips and transfected 
with control vector or plasmids encoding specific genes by Lipofectamine 2000 
(Invitrogen, #11668019) according to the manufacturer’s recommended instruction. For 
transient overexpression in HEK-293T, cells were cultured at 60% confluence on the cell 
culture plates and transfected with control vector or plasmids encoding specific genes by 
using calcium phosphate transfection kit (Clontech, #631312) according to the 
manufacturer’s recommended instruction. 
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Plasmids and siRNAs 
Plasmids encoding HA-MAP1S, GFP–HDAC4, Flag-HDAC4, Flag-HDAC4 
H976Y, Flag-HDAC4 H976F, Myc-HDAC4 H803A, or Myc-HDAC4 D840N were 
previously described (38,59,66,67). The control siRNA (Invitrogen, #AM4635) and 
siRNA specific to human MAP1S (Invitrogen, #AM16708, ID45347) were from 
Invitrogen. The siRNAs specific to human HDAC4 (Santa Cruz, #35540) or mouse 
HDAC4 (Santa Cruz, #35541) were from Santa Cruz Biotechnology. 
Establishment of Stable MAP1S Knockout HeLa Cell Line by CRISPR/Cas9 
Guide RNAs targeting human MAP1S gene listed in the Table 2 were designed 
using Optimized CRISPR Design (http://crispr.mit.edu/). DNA oligos were synthesized 
by Integrated DNA Technologies and annealed by using T4 Polynucleotide Kinase (New 
England Biolabs, #M0201S) according to the manufacturer’s recommended instruction. 
Annealed DNA oligos were inserted into CRISPR/CAS9 vector pSpCas9(BB)-2A-Puro 
(PX459) (Addgene, #48139) via digestion-ligation reaction to construct plasmids 
encoding Cas9 nuclease and guide RNAs targeting for human Map1s. Sequence 
verification was then performed by GENEWIZ. HeLa cells were transiently transfected 
with a pool of five MAP1S CRISPR/Cas9 knockout plasmids or the vector for wild-type 
control. Cells were selected with 1.5 µg/ml puromycin (Sigma, #P9620) starting at 48 
hours after transfection. Multiple monoclonal single cell clones were picked and cultured 
individually in separate wells. Immunoblot analyses of MAP1S protein level were used 
to determine the knockout efficiency. 
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Table 2. DNA Oligos for gRNAs Targeting Human MAP1S. 
 
 
Isolation of Primary Mouse Hepatocytes 
Primary mouse hepatocytes were isolated from 12-week-old male mice. Mice 
were anesthetized and laparotomized with U shape incision. The portal vein was 
cannulated and the inferior vena cava was sectioned. The liver was simultaneously 
perfused with Earle’s Balanced Salt Solution (EBSS) (Invitrogen, #14115-063) 
containing 0.5 mM EGTA (Sigma, #E4378), followed by Hanks’ Balanced Salt Solution 
(HBSS) (Invitrogen, #14170-112) supplied with 0.3mg/ml type IV collagenase (Roche, 
#11088874103). After perfusion, the liver was cut out and gently squeezed until most of 
the hepatocytes got out. The cells were filtered through sterile 70-µm-mesh nylon 
(Greiner Bio-one, #542070), washed by centrifugation and resuspended in the culture 
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media. Cell viability was assessed by trypan blue (Invitrogen, #15250-061) staining and 
cells were seeded at 1×10^6 in the 60 mm dish.  
Immunoblot Analyses 
Cells were lysed in the cell lysis buffer (50 mM HEPES, pH 7.5, 150 mM NaCl, 
1 mM EDTA, 2.5 mM EGTA, 0.1% Triton X-100, 10% Glycerol, 1 mM NaF) with 1 
mM phenylmethanesulfonyl fluoride (PMSF) (Sigma, #P7626) on ice for 30 minutes. 
The total protein concentration of the cell lysates was determined by using BCA protein 
assay kit (Thermo Scientific, #23225). The cell lysates were then mixed with sodium 
dodecyl sulfate (SDS) loading buffer and boiled for 10 minutes. Cell lysates were loaded 
on SDS-polyacrylamide gels containing 8, 10, 12 or 15% (w/v) acrylamide. Proteins 
were separated by electrophoresis, transferred on to polyvinylidene difluoride (PVDF) 
membranes (GE Health, #10600023). The membranes were then blocked with 5% (w/v) 
non-fat milk in Tris-buffered Saline with Tween-20 (TBST) for 1 hour at room 
temperature, bound with primary antibodies overnight at 4 °C and incubated with 
horseradish peroxidase (HRP)-conjugated secondary antibodies (Bio-Rad, #172-1011, 
#170-6515, dilution 1:10000) for 2 hours at room temperature. Proteins were detected by 
ECL Prime Western Blotting Detection Reagents (GE Health, #RPN2232). The exposed 
X-ray films (Pheonix, #F-BX57) were processed using developer (Carestream, 
#1900984) and fixer (Carestream, #1902485), and scanned into image files. The relative 
intensity of a band to internal control was measured using ImageJ software (NIH). The 
catalog numbers and dilutions of primary antibodies are listed in the Table 3. 
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Table 3. Catalog Numbers and Dilutions of Primary Antibodies-I.
Immunoprecipitation 
To analyze levels of acetylated MAP1S by immunoprecipitation, cell lysates 
were prepared by using RIPA buffer (50 mM Tris-Hcl, pH 7.4, 150 mM NaCl, 1% 
Triton X-100, 0.5% sodium dexycholate, 1 mM EDTA, pH 7.4, 0.5 mM EDTA, 0.1% 
SDS) with 1 mM PMSF, protease inhibitor cocktails (Sigma, #P8340), 5 mM 
nicotinamide (NAM) (Sigma, #72340) and 10 µM Trichostatin A (TSA) (Sigma, 
#T8552); and centrifuged at 14,000 rpm for 15 minutes at 4 °C to isolate the 
supernatants. Lysates of same amount of total proteins were mixed with 30 µl anti-
acetyl-lysine agarose conjugate (EMD Millipore, #16-272) overnight at 4 °C for 
precipitation of total acetylated lysine proteins.  
To study the interaction between MAP1S and HDAC4, cell lysates were prepared 
by using NP-40 buffer (50 mM Tris-Hcl, pH 7.4, 150 mM NaCl, 5 mM EDTA, pH 7.4, 1% 
NP-40) with 1 mM PMSF and protease inhibitor cocktails. The supernatants were 
collected after centrifugation at 14,000 rpm for 15 minutes at 4 °C. Same amount of 
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lysates with 1.5 mg of total protein were subjected to immunoprecipitation with 2 µg 
antibodies against MAP1S, HDAC4, HA, or the respective IgG control, and incubated 
with 30 µl Protein G-Sepharose beads (GE Health, #17-0618-01). Beads binding with 
antibodies and the bound proteins were precipitated and washed extensively with the 
relative lysis buffer four times. The final precipitates were resuspended in 100 µl lysis 
buffer containing SDS loading buffer and processed for immunoblot analyses.  
 
GST Pull-down Assay 
HEK-293T cells overexpressing Flag-HDAC4 or a control were lysed with 
binding buffer containing 1% NP-40 in PBS, 2 mM dithiothreitol (Sigma, #D0632) and 
protease inhibitor cocktails. The supernatants were collected after centrifugation at 
14,000 rpm for 15 minutes at 4 °C. Lysates of 200 µg protein were mixed with 25 µl 
equilibrated Glutathione-Sepharose 4B beads (GE Health, #17-0756-01) in a final 
volume of 400 µl and rotated for 30 minutes at 4 °C for per-cleaning. A total of 7.5 µg 
purified Glutathione S-transferase (GST) or GST-tagged proteins bound to 25 µl 
glutathione beads were mixed with 200 µg pre-cleaned cell lysates, and rotated for 1 
hour at 4 °C and then washed three times with binding buffer. The pellets were 
resuspended in 50µl binding buffer containing SDS loading buffer and processed for 






Total RNA was extracted from HeLa cells transfected with control siRNA, 
HDAC4-specific siRNA, control vector plasmid, or HDAC4 expression plasmid with 
Trizol reagent (Invitrogene, #15596-026) according to the manufacturer’s recommended 
instructions. The Invitrogene SuperScript III First-Strand System was used for reverse 
transcription with random primers for cDNA synthesis. Real-time PCRs were performed 
with SYBR Premix ExTaq (TaKaRa, #RR820A) according to the manufacturer’s 
recommended instructions. Primers for human MAP1S included a forward primer 5’-
CGCTGGAAGAACTCCTCATC-3’ and a reverse primer 5’-GAGTGAGCCCAGTGA 
GAAGG-3’ and those for human β-Actin included a forward primer 5’-ACTCTTCCA 
GCCTTCCTTCC-3’ and a reverse primer 5’-CAGTGATCTCCTTCTGCATCC-3’. The 
comparative threshold (CT) cycle method was used to calculate the mRNA level. The 
relative mRNA level of Map1s was quantified by normalizing the amount of Map1s 
mRNA to the amount of β-actin mRNA.  
Protein Half-life Measurement 
HeLa cells were seeded in 10cm culture dishes and transfected with control 
siRNA or HDAC4-specific siRNA. After transfection for 48 hours, cells were processed 
for subculture. Cell pellet harvested after centrifugation at 600 rpm for 5 minutes were 
resuspended and split evenly into 35 mm culture dishes. Then, the protein synthesis 
inhibitor 10 µg/ml cycloheximide (CHX) (Sigma, #C1988) was added into the culture 
media. Cell lysates were harvested at the indicated time points for immunoblot analyses.  
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             Deacetylation 
As described previously (61), 293T cells were transfected with the plasmid 
expressing HA-MAP1S and treated with 1 µM apicidin (Sigma, #A8851) to induce 
acetylated HA-MAP1S 24 hours prior to the harvest. Cell lysates were prepared by using 
RIPA buffer with 1 mM PMSF, protease inhibitor cocktails, 5 mM NAM and 10 µM 
TSA; and purified with anti-MAP1S antibody by immunoprecipitation. Flag-HDAC4, 
Flag-HDAC4 H976Y, Flag-HDAC4 H976F, Myc-HDAC4 H803A, or Myc-HDAC4 
D840N was overexpressed in 293T cells and purified with conjugated anti-Flag M2-
agarose (Sigma, #M8823) or anti-Myc antibody (Cell Signaling, #2276) and Protein G-
agarose beads by immunoprecipitation. The agarose beads containing immunopurified 
HDAC4 were mixed with agarose beads containing HA-MAP1S in deacetylation buffer 
(10 mM Tris-HCl, pH 8.0, 150 mM NaCl and 10% glycerol). Mixture was incubated at 
37°C for the indicated amount of time; each reaction was terminated with SDS loading 
buffer. 
Fluorescence Microscopy 
HeLa-RFP-LC3 cells transfected with the plasmid expressing GFP or GFP-
HDAC4 were treated with 10 nM balifomycin A1 (BAF) (Sigma, #11707) for 6 hours 
before fixation. Cells were fixed with 4% (w/v) paraformaldehyde (Sigma, #P6148) in 
PBS at room temperature for 30 minutes and processed for fluorescence microscopy 
analyses. Images were captured with a Zeiss LSM 510 Meta Confocal Microscope. The 
In vitro  
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acquired images were converted into 8-bit binary files, and the number of RFP-LC3 
punctate foci on each image was calculated using ImageJ software. 
Transmission Electron Microscopy 
HeLa cells, transfected with control siRNA, HDAC4-specific siRNA, control 
vector plasmid or Flag-HDAC4 plasmid, were treated with 10 nM BAF for 12 hours 
before fixation. As described previously (58), cells were fixed for 1 hour with a solution 
containing 3% (w/v) glutaraldehyde, 2% (w/v) paraformaldehyde and 0.1M cacodylate 
buffer, pH 7.3. After fixation, cells were washed and treated with 0.1% Millipore-filtered 
cacodylate-buffered tannic acid, post-fixed with 1% (w/v) buffered osmium tetroxide for 
30 minutes, and stained en bloc with 1% (w/v) Millipore-filtered uranyl acetate. The 
samples were dehydrated in increasing concentrations of ethanol, infiltrated and 
embedded in LX-112 medium followed by polymerization in a 70 °C oven for 2 days. 
Ultrathin sections were cut in a Leica Ultracut microtome (Leica), stained with uranyl 
acetate and lead citrate in a Leica EM Stainer, and examined in a JEM 1010 transmission 
electron microscope (JEOL) at an accelerating voltage of 80 kV. Digital images were 
obtained using the Advanced Microscopy Techniques imaging systems. The percentages 
of areas occupied by autophagic vacuoles were measured using ImageJ software.  
Statistical Analyses 
Statistical significance was determined by Student’s t-test, with significance set 
to *, p≤0.05; **, P≤0.01; and ***, P≤0.001. Error bars indicate standard deviation. 
23 
Results 
MAP1S Deficiency Results in Autophagy Suppression 
To study the impact of MAP1S on regulating autophagic flux, lysosome inhibitor 
bafilomycin 1A (BAF) was applied to inhibit autolysosomal degradation and levels of 
accumulated LC3-II was measured to represent autophagic flux by immunoblot analyses. 
Effective transient siRNA knockdown of MAP1S in HeLa (Figure 1A) and HepG2 
(Figure 1B) cells leads to increased levels of LC3-II but decreased levels of accumulated 
LC3-II when cells were treated with 10 nM BAF for 4 hours, which suggested that 
MAP1S knockdown inhibited both autophagy initiation and degradation. 
The suppressive role of MAP1S deficiency in autophagy was further confirmed 
in HeLa cell lines with stable knockout of MAP1S. CRISPR/Cas9 technique was applied 
to establish MAP1S-/- HeLa cells and three single cell colonies were isolated. As shown 
in the results of immunoblot analyses, MAP1S-/- HeLa cells accumulated less LC3-II 
compared to MAP1S+/+ HeLa cells after BAF treatment (Figure 1C), which suggested 
depletion of MAP1S suppressed autophagic flux. Meanwhile, mouse embryonic 
fibroblasts (MEF) and primary mouse hepatocytes isolated from wild-type or MAP1S-/- 
mice were treated with BAF to study the role of MAP1S on autophagy. Significant 
decrease in levels of LC3-II was observed in MAP1S-/- MEF cells (Figure 1D) or 
MAP1S-/- hepatocytes (Figure 1E) in contrast to wild-type MEF cells or wild-type 
hepatocytes after BAF treatment, which also demonstrated MAP1S deficiency resulted 
in autophagy suppression. All the results confirm that MAP1S is a positive regulator of 
autophagic flux.  
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Figure 1. Depletion of MAP1S Suppresses Autophagic Flux. (A, B) Transient siRNA 
knockdown of MAP1S inhibits autophagic flux. Representative immunoblot results 
show the impact of MAP1S suppression with siRNA on levels of LC3-II in HeLa (A) or 
HepG2 cells (B) in the absence (Ctrl) or presence of BAF. (C-E) Knockout of MAP1S 
suppresses autophagic flux. Representative immunoblot results of levels of LC3-II in 
wild-type and MAP1S-/- HeLa cells (C), wild-type and MAP1S-/- MEF cells (D), wild-
type and MAP1S-/- primary mouse hepatocytes (E), in the absence (Ctrl) or presence of 
BAF, are shown. 
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HDAC Inhibitor Apicidin Enhances Levels of Acetylated MAP1S and Promotes 
Autophagic Flux 
Similarly to the previous results (68), the histone deacetylase inhibitor, apicidin 
was able to induce autophagy. HeLa cells treated with 1µM apicidin for 24 hours had 
increased levels of LC3-II compared to HeLa cells treated with dimethyl sulfoxide 
(DMSO) control in the absence or presence of BAF for 4 hours (Figure 2A, B), which 
suggested apicidin promoted autophagic flux. As shown in the immunoblot results, 
apicidin also led to increased levels of MAP1S protein in both HeLa and COS-7 cells 
(Figure 2C), suggesting MAP1S may participate in the regulation of apicidin-induced 
autophagy. In addition, the total acetyl-lysine proteins were first precipitated by anti-
acetyl-lysine agarose conjugate, and then levels of acetylated MAP1S were analyzed by 
immunoblot analyses. Apicidin enhanced levels of acetylated MAP1S as well (Figure 
2D, E), suggesting the acetylation of MAP1S may be involved in regulating MAP1S and 
apicidin-induced autophagy.   
HDAC4 Interacts with MAP1S 
A yeast two-hybrid screen result reported previously suggested MAP1S might 
bind to HDAC4 (65). Here, the interaction between endogenous MAP1S and HDAC4 
was confirmed in HeLa cells by immunoprecipitation using MAP1S-specific monoclonal 
antibodies (Figure 3A). Further examination of the interaction was characterized with 
either HA- or MAP1S-specific antibodies in 293T cells transiently overexpressing both 
HDAC4 and HA-fused MAP1S (HA-MAP1S) (Figure 3B, C). 




Figure 2. HDAC Inhibitor Apicidin Enhances the Acetylation of MAP1S and 
Promotes Autophagic Flux. (A, B) Apicidin induces autophagic flux. Representative 
immunoblot results (A) and quantification (B) show the impact of apicidin on levels of 
LC3-II in HeLa cells, in the absence (None) or presence of BAF. (C) Apicidin enhances 
levels of MAP1S protein. Representative immunoblot results show the impact of 
apicidin on levels of MAP1S protein in HeLa or COS-7 cells. (D, E) Apicidin enhances 
levels of acetylated MAP1S. Representative immunoblot results (D) and quantification 




Figure 3. HDAC4 Interacts with MAP1S. (A) Endogenous HDAC4 interacts with 
MAP1S. HeLa cell lysates were precipitated with MAP1S-specific antibodies or IgG 
control. (B, C) Exogenous HDAC4 interacts with MAP1S in 293T cells overexpressing 
both HDAC4 and MAP1S. Lysates of 293T cells overexpressing both HDAC4 and HA-
MAP1S were precipitated with specific antibodies against HA, MAP1S, or IgG control 
(B). Lysates of normal 293T cells and 293T cells overexpressing both HDAC4 and HA-
MAP1S were precipitated with MAP1S-specific antibodies or IgG control (C). 
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HDAC4 Negatively Regulates MAP1S 
To assess potential function of the interaction between HDAC4 and MAP1S, the 
impact of cellular levels of one on the other was analyzed by immunoblot analyses. The 
siRNA-mediated transient knockdown of MAP1S in HeLa cells (Figure 4A), transgenic 
deletion of MAP1S in MEF cells (Figure 4B) or multiple mouse tissues (Figure 4C), or 
overexpression of MAP1S isoforms (Figure 4D) in HeLa cells had no obvious impact on 
levels of HDAC4 protein. Meanwhile, levels of HDAC4 protein were altered to test if 
levels of MAP1S protein would be changed concomitantly. Transient transfection of 
293T cells with increasing amounts of HDAC4 plasmid caused gradient decrease in 
levels of MAP1S protein (Figure 4E). In contrast, suppression of HDAC4 expression 
with siRNA caused elevation in levels of MAP1S protein in both HeLa and COS-7 cells 
(Figure 4F.) All the results suggest that HDAC4 negatively regulates MAP1S.  
 
HDAC4 Destabilizes MAP1S via Deacetylation 
To explore the mechanism by which HDAC4 regulates MAP1S, levels of Map1s 
mRNA were first analyzed by quantitative real-time PCR. Neither suppression of 
HDAC4 by transient siRNA knockdown nor enhancement of HDAC4 protein by 
transient overexpression in HeLa cells had any impact on levels of Map1s mRNA 
(Figure 5A), which suggested that HDAC4 might regulate MAP1S through post-
translational modification rather than transcriptional regulation. Meanwhile, the half-life 
of MAP1S protein was measured in the presence of protein synthesis inhibitor 
cycloheximide (CHX) in HeLa cells transfected with control or HDAC4-specific siRNA.  
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Figure 4. HDAC4 Negatively Regulates MAP1S. (A-C) MAP1S depletion has no 
impact on levels of HDAC4 protein in HeLa cells treated with MAP1S-specific siRNA 
(A), MEF cells (B) or mouse tissues (C) derived from wild-type or MAP1S-/- mice. 
Representative immunoblot results are shown. (D) Overexpression of MAP1S isoforms 
has no impact on levels of HDAC4 protein in HeLa cells. Representative immunoblot 
results are shown. (E) Overexpression of HDAC4 results in decreased levels of MAP1S. 
Representative immunoblot results show increasing expression of HDAC4 causes dose-
dependent reduction in levels of MAP1S protein in 293T cells. (F) Suppression of 
HDAC4 results in increased levels of MAP1S protein. Representative immunoblot 
results show HDAC4 depletion with siRNA increases levels of MAP1S in HeLa or 
COS-7 cells. 
30 
Figure 5. HDAC4 Destabilizes MAP1S via Deacetylation. (A) HDAC4 suppression or 
overexpression does not alter levels of Map1s mRNA. The plot shows relative levels of 
Map1s mRNA in HeLa cells transfected with siRNA to suppress the expression of 
HDAC4 or with plasmid to overexpress HDAC4. (B, C) HDAC4 depletion increases the 
stability of MAP1S protein. HeLa cells were treated with random (Mock) or HDAC4-
specific siRNA (HDAC4), and cellular protein synthesis was then terminated with 10 
µg/ml cycloheximide (CHX). Samples were collected at different times after CHX 
treatment. Representative immunoblot results (B) and quantification (C) are shown. (D, 
E) HDAC4 reduces levels of acetylated MAP1S. HDAC4 was purified from 293T cells
overexpressing HDAC4 by immunoprecipitation with specific antibodies against 
HDAC4; purified HDAC4 (Active) was inactivated by boiling (Inactive). MAP1S 
purified from 293T cells overexpressing MAP1S with specific antibodies against 
MAP1S was incubated with increasing amounts of active HDAC4 for 2 hours (D) or 
same amount of HDAC4 for increasing amounts of incubation time (E). Representative 
immunoblot results are shown. 
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Results indicated that suppression of HDAC4 increased the stability of MAP1S protein 
(Figure 5B, C). 
To demonstrate that HDAC4 activity directly could directly affect the acetylation 
of MAP1S, immunoprecipitates of HA-MAP1S were incubated with immuno-purified 
active HDAC4. Levels of acetylated MAP1S were inversely proportional to increasing 
levels of HDAC4 (Figure 5D) as well as the time of incubation with HDAC4 (Figure 5E). 
In contrast, no significant decrease in levels of acetylated MAP1S was observed when 
immunoprecipitates of HA-MAP1S were incubated with heat-inactivated HDAC4 
(Figure 5E).  
The degree of MAP1S acetylation when incubated with gain or loss of function 
mutants of HDAC4 (59,66) was further investigated. As expected, mutant H976Y that 
has a reported gain in activity relative to wild-type HDAC4 exhibited significantly 
higher MAP1S-deacetylation activity and lower levels of acetylated MAP1S than wild-
type HDAC4. HDAC4 mutant H803A and D840N that have compromised catalytic 
activity each exhibited significantly lower MAP1S-deacetylation activity and higher 
levels of acetylated MAP1S than wild-type HDAC4. Unexpectedly, incubation of 
MAP1S with the H976F mutant resulted in decreased deacetylation and increased levels 
of acetylated MAP1S relative to wild-type HDAC4 (Figure 6A, B). The H976F mutant 
has been reported to be similar to wild-type HDAC4 using other substrates. These results 
show clearly that HDAC4 regulates MAP1S deacetylation.  
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Figure 6. HDAC4-induced Deacetylation of MAP1S Depends on HDAC4 Catalytic 
Activity. (A, B) HDAC4 mutants with increased or reduced activity exhibit reduced or 
enhanced catalytic activity on deacetylating MAP1S. HDAC4 mutant proteins purified 
in the same method as wild-type HDAC4 were incubated with purified MAP1S for 1 
hour. Representative immunoblot results (A) and quantification (B) are shown. 
HDAC4 Inhibits Autophagic Flux through MAP1S 
MAP1S functions as an autophagy activator, but is negatively regulated by 
HDAC4. To study the impact of HDAC4 on autophagy, levels of LC3 were examined 
when cells transfected with HDAC4 plasmid or HDAC4-specific siRNA in the presence 
of BAF. Impairment of autophagic flux due to HDAC4 overexpression was confirmed 
by reduced levels of LC3-II in HeLa cells in the presence of BAF (Figure 7A, B). 
Suppression of HDAC4 with siRNA (Figure 7C, D) resulted in increased levels of 
MAP1S, which was accompanied by increased levels of LC3-II in the presence of BAF.  
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Figure 7. HDAC4 Inhibits Autophagic Flux Indicated by Immunoblot Analyses. (A-
D) HDAC4 affects levels of MAP1S and LC3-II. Representative immunoblot results (A, 
C) and respective quantification (B, D) show the impact of HDAC4 overexpression (A,
B) or HDAC4 suppression with siRNA (C, D) on levels of MAP1S and LC3 in HeLa
cells, in the absence (Ctrl) or presence of BAF. 
Autophagic flux measured at the cellular level by punctate foci of RFP-LC3 
observed by fluorescence microscopy was impaired by HDAC4 overexpression (Figure 
8A, B). Autophagic flux measured by autophagy vacuoles observed under the electron 
microscope was impaired by overexpression of HDAC4 (Figure 8C, D), or enhanced by 
suppression of HDAC4 (Figure 8C, E). 
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Figure 8. HDAC4 Inhibits Autophagic Flux Indicated by Fluorescence and Electron 
Microscopy. (A, B) HDAC4 overexpression reduces the number of punctate foci of 
RFP-LC3 in HeLa cells stably expressing RFP-LC3. Fluorescence microscopy images 
(A) and quantification (B) of punctate foci of RFP-LC3 in the absence (Ctrl) or presence 
of BAF are shown. (C-E) HDAC4 overexpression (C, D) or siRNA suppression (C, E) 
alters the vacuolar areas in HeLa cells. Transmission electron microscopic images (C) 
and quantification (D, E) are shown. Symbol “*” indicates vacuoles in (C).  
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Figure 8. Continued.  
 
To determine whether the regulation of autophagic flux by HDAC4 depends on 
MAP1S, MAP1S-/- MEF cells or MAP1S-/- HeLa cells were utilized. Impairment of 
autophagic flux by overexpression of HDAC4 (Figure 9A, B) or the activation of 
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autophagic flux by suppression of HDAC4 (Figure 9C, D) was only evident in wild-type 
cells where MAP1S was present; and the effect of alteration in levels of HDAC4 protein 
was abrogated in MAP1S-/- cells (Figure 9A-D).  All the results suggest that HDAC4 
inhibits autophagic flux through MAP1S. 
Figure 9. HDAC4 Inhibits Autophagic Flux through MAP1S. (A-D) MAP1S is 
required for HDAC4 to affect levels of LC3-II. Representative immunoblot results (A, C) 
and quantification (B, D) show the impact of MAP1S deletion on the effect of HDAC4 
overexpression in wild-type and MAP1S-/- MEF cells (A, B) or HDAC4 suppression 
with siRNA in wild-type and MAP1S-/- HeLa cells (C, D) on levels of LC3-II in the 
absence (Ctrl) or presence of BAF. 
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Discussion 
HDACs-mediated histone deacetylation is a key epigenetic modification that has 
attracted enormous attention (20,69). Deacetylation of non-histone proteins uncovers the 
roles of HDACs in controlling cellular function as well (70). P53 is the first reported 
transcription factor regulated via acetylation (71), among other acetylation-regulated 
transcription factors including STAT3, c-Myc, NF-κB, etc (70). Acetylation of P53 
increases its protein stability and the binding affinity with DNA, resulting in increased 
transcriptional activity (71,72). HDAC1 interacts with and deacetylates P53, promoting 
the proteasomal degradation of P53 (73). In addition to transcription factors, 
deacetylation of α-tubulin is catalyzed by HDAC6 to increase microtubule 
depolymerization and cell motility (74,75). By regulating microtubule dynamics, 
HDAC6 is involved in the regulation of autophagy and mitophagy (76-79). Herein, we, 
for the first time, report that another member in ClassII HDACs, HDAC4, regulates 
autophagy by inducing deacetylation of autophagy activator MAP1S. Meanwhile, our 
study implies that HDAC5 may participate in autophagy, in addition to HDAC4 and 
HDAC6. LRPPRC is a binding protein of MAP1S and suppressor of autophagy initiation 
by enhancing levels of Bcl-2 (58). The interaction between HDAC5 and LRPPRC 
potentiates the ability of HDAC5 in autophagy regulation (80). 
HDAC4 was originally characterized as a transcriptional regulator that associates 
and regulates transcription factor MEF2-mediated gene expression together with 
HDAC5 (59,81,82). It seems that HDAC4 regulates transcription of a specific set of 
genes by affecting the stability of the related transcriptional factors instead of the general 
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epigenetic modification of genome-associated histones (20). Though HDAC4 was 
suggested to directly deacetylate HIF-1α in vitro (61), it was reported that HDAC4 alone 
does not show deacetylase activity on histone substrates but regulates histone 
deacetylation through the formation of a functional complex by interacting with HDAC3 
(83). In this study, we demonstrate that HDAC4 catalyzes the deacetylation of MAP1S; 
no matter HDAC4 exerts its deacetylase activity on MAP1S directly or indirectly 
through HDAC3 (20). 
MAP1S is a microtubule-associated protein that binds with autophagy marker 
LC3 to facilitate autophagosomal formation and degradation. It may also regulate 
autophagy initiation through Bcl-2 and P27 in a Beclin 1-independent pathway (41). By 
accelerating autophagic flux, MAP1S reduces cellular oxidative stress and prolongs 
lifespans in mice (4). Besides, activation of MAP1S-mediated autophagy suppresses 
tumorigenesis (33) and extends survival of cancer patients (35,36). Unraveling the 
mechanism for enhancing levels of MAP1S protein provides insights on activation of 
MAP1S-mediatied autophagy. In this study, we, for the first time, report that MAP1S is 
regulated via acetylation and deacetylation, and identify HDAC4 as a negative regulator 
of MAP1S. The acetylation of MAP1S increases the stability of MAP1S protein and 
further promotes autophagic flux. HDAC4 interacts with MAP1S and catalyzes the 
deacetylation of MAP1S, leading to destabilization of MAP1S and further inhibits 
autophagic flux. The suppressive role of HDAC4 in autophagy is mediated by decreased 
levels of MAP1S protein. This study reveals a new strategy to activate MAP1S-mediated 
autophagy by inhibiting HDAC4. At present, the specific lysine acetylation sites of 
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MAP1S regulated by HDAC4 have not been determined. A mass spectrometry analysis 
may be conducted to identify the specific lysine acetylation sites in the future, which will 
contribute to understanding the molecular detail of MAP1S protein. 
A variety of ATG proteins are regulated by acetylation and deacetylation process, 
including ATG5, ATG7, ATG8, and ATG12 (84). As reported, these autophagy 
components are acetylated by p300 acetyltransferase (85) or deacetylated by SIRT1 
deacetylase (86). Interestingly, the acetylation of these ATG proteins plays a negative 
role in autophagy, which is opposite to the positive role of acetylation in MAP1S and 
MAP1S-mediated autophagy. Thus, our study opens a new field of discovery on the 
roles of acetylation and deacetylation in other autophagy-relevant proteins.  
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CHAPTER III  
ACETYLATED MAP1S ACCELERATES AUTOPHAGIC CLEARANCE OF 
MUTANT HUNTINGTIN AGGREGATES*2 
 
Introduction 
Huntington’s disease (HD) is a fatal progressive neurodegenerative disorder 
caused by the accumulation of mutant Huntingtin proteins (mHTT) in neurons. Wild-
type Huntingtin (HTT) has 6-35 ployglutamine (polyQ) expansion in the N-terminus of 
HTT protein, while mHTT has more than 36 polyQ expansion, which leads to mHTT 
prone to form insoluble aggregates by both hydrogen and covalent bonds. These 
aggregates are toxic to neurons and further lead to neuronal degeneration. As there is no 
effective treatment for HD at present, HD patients suffer from progressive loss of 
cognition and motor function, and ultimately death within 10-20 years after first 
appearance of the symptom for diagnosis (23). 
Autophagy is a cellular self-digestion process that begins with the formation of 
isolation membranes that recognize and engulf substrates, including aggregated proteins, 
to form autophagosomes. These autophagosomes migrate along acetylated microtubules 
and fuse with lysosomes to generate autolysosomes in which autophagosomal cargos are 
                                                
*Part of this chapter is reprinted with permission from “Blocking the Association of 
HDAC4 with MAP1S Accelerates Autophagy Clearance of Mutant Huntingtin” by Yue, 
F., Li, W., Zou, J., Chen, Q., Xu, G., Huang, H., Xu, Z., Zhang, S., Gallinari, P., Wang, 
F., McKeehan, W. L., and Liu, L, 2015, Aging 7, 839-853, Copyright [2015] by Fei Yue. 
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degraded (6,20,87). Autophagy deficiency causes accumulation of toxic mHTT 
aggregates in neurons and further results in neuronal death (88). Therefore, enhancement 
of autophagy activity to accelerate the turnover of mHTT aggregates is one of the 
directions to develop therapeutics for HD. 
As a novel microtubule-associated autophagy activator, microtubule-associated 
protein 1 small form (MAP1S) can enhance autophagy initiation and accelerate 
autophagy degradation. Based on previous reports, MAP1S is suggested to be involved 
in neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and 
Huntington’s disease. N-methyl-D-aspartate receptor (NMDAR) facilitates endocytic 
removal and replacement of surface receptor at synapses, which is essential in mediating 
learning and memory (89,90). MAP1S can interact with NR3A, one of the subunits of 
NMDAR, and have a potential role in the degradation of NMDAR and development of 
dementia which is a major symptom of Alzheimer’s disease (91). In addition, MAP1S 
can bind with leucine-rich pentatricopeptide repeat containing (LRPPRC) (37) that also 
interacts with mitophagy initiator Parkin and protects mitochondria from autophagy 
degradation (58,92), suggesting MAP1S may participate in the regulation of molecular 
pathogenesis of Parkinson’s disease. Histone deacetylases 4 (HDAC4) has been 
identified as a potential target to ameliorate Huntington’s disease. Studies showed that 
HDAC4 interacts with mHTT and co-localizes in the cytoplasmic inclusion bodies (93). 
As discussed in chapter II, HDAC4 interacts with MAP1S and decreases the stability of 
MAP1S protein via deacetylation (20), which suggests MAP1S may regulate mHTT 
degradation through autophagy. 
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In the mouse models of Huntington’s disease, HDAC4 reduction alleviates 
cytoplasmic formation of mHTT aggregates and rescues neuronal and cortico-striatal 
synaptic function, but does not repair the global transcriptional dysfunction (93). 
However, the mechanism by which HDAC4 reduction delays cytoplasmic formation of 
mHTT aggregates is unknown (20). HDAC4 suppresses autophagy by negatively 
regulating autophagy activator MAP1S, which prompts us to study whether HDAC4 
regulates autophagy to affect mHTT aggregation through MAP1S. Elevating levels of 
MAP1S protein by either inhibition of HDAC4 or interruption of the interaction between 
HDAC4 and MAP1S may promote autophagic clearance of mHTT and ameliorate 
Huntington’s disease. 
 Herein, we first confirm that HDAC4 associates with mHTT aggregates in the 
cytoplasm. HDAC4 leads to accumulation of mHTT aggregates by down-regulating 
MAP1S and inhibiting MAP1S-mediated autophagic turnover of mHTT aggregates. In 
addition, we identify an HDAC4-binding domain (HBD) within the overlapping region 
between the heavy chain (HC) and short chain (SC) of MAP1S, which is responsible for 
the interaction between HDAC4 and MAP1S. Overexpression of HBD interrupts the 
association of MAP1S with HDAC4 and leads to increased levels of MAP1S protein. 
Inhibition of HDAC4 or overexpression of HBD promotes stabilization of MAP1S and 
restores MAP1S-regulated autophagic flux and degradation of mHTT aggregates, 
suggesting a novel approach to treat Huntington’s disease (20). 
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Materials and Methods 
Cell Culture 
Most cell lines, including HeLa, HEK-293T, HeLa cells stably expressing 
inducible GFP-HTT72Q (HeLa-GFP-HTT72Q), and MEF cells were cultured in the 
DMEM culture media containing 10% FBS and antibiotics. Neuro-2α (N2α) cells were 
grown in Eagle's Minimum Essential Medium (EMEM) (ATCC, #30-2003) with 10% 
FBS and antibiotics. PBS and 0.25% trypsin were used for subculture. 
 
Cell Transfection 
Cell lines used for transfection included HeLa, HEK-293T, HeLa-GFP-HTT72Q 
cells, MEF cells, or N2α cells. For transient knockdown experiments, cells were cultured 
at 30% confluence on the cell culture plates or coverslips and transfected with negative 
control siRNA or specific siRNA by Oligofectamine according to the manufacturer’s 
recommended instruction. For transient overexpression experiments in HeLa, HeLa-
GFP-HTT72Q cells, MEF cells, or N2α cells, cells were cultured at 70% confluence on 
the cell culture plates or coverslips and transfected with control vector or plasmids 
encoding specific genes by Lipofectamine 2000 according to the manufacturer’s 
recommended instruction. For transient overexpression in HEK-293T cells, cells were 
cultured at 60% confluence on the cell culture plates and transfected with control vector 
or plasmids encoding specific genes by using calcium phosphate transfection kit 
according to the manufacturer’s recommended instruction. 
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Establishment of Stable Cell Line Expressing Inducible GFP-HTT72Q 
Lenti-XTM Tet-Off Advanced Inducible Expression System (Clontech, #632163) 
was used according to the manufacturer’s recommended instruction to generate the 
inducible GFP-HTT72Q stable cell lines. Briefly, an EGFP-tagged Huntingtin fragment 
encoded by human huntingtin exon 1 plus 72Q repeats was amplified from the pUAST-
Httex1-Q72-eGFP construct as previously described (94) and subcloned into the pLVX-
Tight-Puro vector. Lenti-viruses containing Httex1-Q72 plasmid (pLVX-tight-Q72) and 
the regulator plasmids (pLVX-Tet-OFF advanced) were produced using the Lenti-X 
HTX packaging system (Clontech, #PT5135-2) and used to infect HeLa cells as 
instructed. A combination of 2 µg/ml puromycin and 200 µg/ml neomycin was applied 
to screen for positive clones that were maintained in the “off” state in the presence of 
100 ng/ml doxycycline during the whole selection process to turn off the expression of 
potentially toxic HTT72Q proteins. 
 
Fluorescence Microscopy 
HeLa-GFP-HTT72Q cells transfected with the control vector or plasmid 
expressing Flag-HDAC4 were treated with 10 nM BAF for 12 hours before fixation. 
Cells were fixed with 4% (w/v) paraformaldehyde in PBS at room temperature for 30 
minutes and then permeabilized with 0.1% Triton X-100 (Sigma, #T9284) in PBS for 20 
minutes. Cells were blocked with 1% Bovine Serum Albumin (BSA) (EMD Millipore, 
#2960) in PBS for 20 minutes, and then incubated with primary antibodies against 
HDAC4 (Santa Cruz, #11418, dilution 1:50) or LAMP2 (Santa Cruz, #18822, dilution 
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1:50) for 1 hour at room temperature, and the corresponding rhodamine-conjugated 
secondary antibodies (Invitrogen, #R-6394, #R-6393, dilution 1:400) for 1 hour at room 
temperature for fluorescence microscopy analyses. Primary and secondary antibodies 
were diluted in PBS with 1% BSA. Images were captured with a Zeiss LSM 510 Meta 
Confocal Microscope. The ImageJ software was used to calculate the intensities of GFP-
HTT72Q and analyze the lysosome-associated GFP-HTT72Q aggregates on each image.  
Plasmids and Site-directed Mutagenesis 
HA-MAP1S isoforms (HA-LC, HA-SC, HA-HC and HA-FL) have been 
described earlier (38). Plasmid encoding GFP-HTT74Q (Addgene, #40262) was 
purchased from Addgene. HA-MAP1S R653-Q855 fragment, representing the HDAC4-
binding domain (HBD) of MAP1S, was PCR-amplified with forward primer 5’-ACGCG 
TCGACACGGCTGTCGCTGAGCCCACT-3’ and reverse primer 5’-GAAGATCTCT 
ATTGCCGTGCTGTCTTGGG-3’. The fragment was inserted into HA-PCMV plasmid 
(Clontech, #631604) via digestion-ligation reaction to construct plasmid encoding HA-
HBD. Sequence verification was then performed by GENEWIZ. To delete the HBD 
fragment from the full length MAP1S to generate a deletion construct HA-HBD∆, a pair 
of primers (5’-CTCGCTGCCCTCTGCGGGGCT-3’ and 5’-ACGGAGAACGTCAGC 
CGCACC-3’) were phosphorylated with T4 polynucleotide kinase and mixed with HA-
MAP1S plasmid template to amplify the HA-HBDΔ by PCR using the KOD hot start 
DNA polymerase from TOYOBO. The restriction enzyme DpnI was added to the PCR 
reaction mixture to digest the template. T4 DNA Ligase (New England Biolabs, #M0202) 
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was used to ligate the PCR product to become a circular plasmid which was then verified 
by DNA sequencing. 
Immunoblot Analyses 
Cells were lysed in the cell lysis buffer with 1mM PMSF on ice for 30 minutes. 
The total protein concentration of the cell lysates was determined by using BCA protein 
assay kit. The cell lysates were then mixed with SDS loading buffer and boiled for 10 
minutes. To analyze levels of aggregated GFP-HTT72Q/74Q, cells were lysed in 
isolation buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 5 mM MgCl2, 0.5% NP-40, 
and protease inhibitor cocktails). Insoluble pellets were isolated after 10 minutes 
centrifugation at 14,000 rpm at 4 °C and resuspended in buffer containing 20 mM Tris-
HCl, pH 8.0, 15 mM MgCl2 and 0.5 mg/ml DNase, and then incubated at 37 °C for 1 
hour. Insoluble fractions were diluted in SDS loading buffer and boiled for 5 minutes. 
Cell lysates were loaded on SDS-polyacrylamide gels containing 8, 10, 12 or 15% (w/v) 
acrylamide. Proteins were separated by electrophoresis, transferred on to PVDF 
membranes. The membranes were then blocked with 5% (w/v) non-fat milk in TBST for 
1 hour at room temperature, bound with primary antibodies overnight at 4 °C and 
incubated with HRP-conjugated secondary antibodies for 2 hours at room temperature. 
Proteins were detected by ECL Prime Western Blotting Detection Reagents. The 
exposed X-ray films were processed using developer and fixer, and scanned into image 
files. The relative intensity of a band to internal control was measured using ImageJ 
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software. Antibody against GFP (Santa Cruz, #8334, dilution 1:2000) was applied to 
detect GFP-HTT72Q/74Q. 
Agarose Gel Electrophoresis for Resolving Aggregates 
Agarose gel electrophoresis for resolving aggregates (AGERA) was performed 
following a described protocol (95). Cell lysates containing 100 µg of total protein were 
loaded to a 1.5% agarose gel containing 0.1% SDS for AGERA. The agarose gel was 
run at 100 V and semi-dry transfer was conducted at 200 mA for 1 hour. After transfer, 
the PVDF membrane was further processed for immunoblot analyses. 
Co-immunoprecipitation 
Cell lysates were prepared by using NP-40 buffer with 1 mM PMSF and protease 
inhibitor cocktails. The supernatants were collected after centrifugation at 14,000 rpm 
for 15 minutes at 4 °C. Same amount of lysates with 1.5 mg of total protein were 
subjected to immunoprecipitation with 2 µg antibodies against MAP1S, HDAC4, HA, or 
the respective IgG control, and incubated with 30 µl Protein G-Sepharose beads. After 
overnight rotation at 4 °C, beads that bind with antibodies and the bound proteins were 
precipitated and washed extensively with the NP-40 buffer four times. The final 
precipitates were resuspended in 100 µl lysis buffer containing SDS loading buffer and 
boiled for 10 minutes for further immunoblot analyses.  
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Protein Half-life Measurement 
HEK-293T cells were seeded in 10cm culture dishes and transfected with 
plasmids encoding HA, HA-HBD, or HA-HBD∆ by using calcium phosphate 
transfection kit according to the manufacturer’s recommended instruction. After 
transfection for 24 hours, cells overexpressing HA, HA-HBD, or HA-HBD∆ were 
processed for subculture respectively. Cell pellets harvested after centrifugation at 600 
rpm for 5 minutes were resuspended and split evenly into 35 mm culture dishes. Then, 
the protein synthesis inhibitor 10 µg/ml CHX was added into the culture media once 
cells were attached on the dishes. Cell lysates were harvested at the indicated time points 
for further immunoblot analyses. 
Statistical Analyses 
Statistical significance was determined by Student’s t-test, with significance set 
to *, p≤0.05; **, P≤0.01; and ***, P≤0.001. Error bars indicate standard deviation. 
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Results 
Overexpression of HDAC4 Induces Mutant Huntingtin Aggregation 
GFP-HTT72Q, a GFP-tagged mHTT variant, includes a polypeptide encoded by 
exon 1 of the huntingtin gene plus 72 expanded polyQ repeats in the N-terminus (96,97). 
The acetylation of Huntingtin at K444 residue promotes autophagic degradation of 
Huntingtin itself (98). The K444 residue is out of the sequence covered by HTT72Q so 
that HTT72Q degradation is not affected by the acetylation of K444. To study the impact 
of HDAC4 on mHTT aggregation, HeLa cells stably expressing inducible GFP-HTT72Q 
were established first (20). Overexpression of HDAC4 in cells expressing GFP-HTT72Q 
Figure 10. HDAC4 Induces Mutant Huntingtin Aggregation Indicated by 
Fluorescence Microscopy. (A, B) Overexpression of HDAC4 increases levels of GFP-
HTT72Q (HTT72Q) in HeLa cells stably expressing HTT72Q. Representative 
fluorescent images (A) and the respective quantification (B) are shown. Bars in (A) were 
50 µm in the normal view on the top or 2 µm in the enlarged view on the bottom.  
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led to enhancement of GFP-HTT72Q fluorescence (Figure 10A, B) and increased levels 
of GFP-HTT72Q aggregates detected by immunoblot analyses using anti-GFP 
antibodies (Figure 11A, B). As shown in the fluorescent images, increased levels of 
HDAC4 were distributed surrounding the HTT72Q aggregates (Figure 10A). In contrast, 
suppression of HDAC4 with HDAC4-specific siRNA led to reduction in levels of mHTT 
aggregates (Figure 11C, D). Furthermore, analyses with agarose gel electrophoresis for 
resolving aggregates (AGERA) (Figure 11F) were utilized to measure levels of mHTT 
aggregates, and revealed the same results as in the normal immunoblot analyses of 
aggregates in the stacking gel (Figure 11E). Accumulation of another mHTT variant, 
GFP-HTT74Q, with a similar role as GFP-HTT72Q in HD, was observed when GFP-
HTT74Q and HDAC4 were transiently co-overexpressed in neuroblastoma Neuro-2α 
(N2α) cells (Figure 11E-G). Thus, overexpression of HDAC4 significantly increases the 
severity of mHTT aggregation. 
Consistent with a previous report (24), GFP-HTT72Q was degraded in lysosomes. 
Inhibition of lysosomal activity with BAF led to accumulation of mHTT aggregates 
together with the autophagy marker LC3-II (Figure 12A). The percentage of GFP- 
HTT72Q aggregates that overlapped with lysosome-associated membrane protein 2 
(LAMP2)-labeled lysosomes was significantly increased in the presence of BAF (Figure 
12B, C). This suggests that small aggregates are efficiently degraded through lysosomes 
in the absence of BAF, but large aggregates accumulate due to compromised lysosomal 
degradation. 
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Figure 11. HDAC4 Induces Mutant Huntingtin Aggregation Indicated by 
Immunoblot Analyses. (A, B) Overexpression of HDAC4 increases levels of GFP-
HTT72Q (HTT72Q) in HeLa cells stably expressing HTT72Q. Representative 
immunoblot results (A), and the respective quantification (B) are shown. HTT72Q 
aggregates retained in stacking gel (stk) and soluble HTT72Q (sol) were labeled. The 45 
KD HTT72Q formed aggregates that failed to penetrate into stacking gel. (C, D) 
Suppression of HDAC4 decreases levels of HTT72Q aggregates in HeLa cells stably 
expressing HTT72Q. Representative immunoblot results (C) and quantification (D) 
show the impact of HDAC4 suppression with siRNA on levels of HTT72Q aggregates. 
(E-G) Overexpression of HDAC4 increases levels of GFP-HTT74Q (HTT74Q) in N2α 
cells transiently expressing HTT74Q. Representative results from immunoblot analyses 
of aggregates in stacking gel (E) or AGERA (F), and the respective quantification (G) 
are shown. 




Figure 12. Mutant Huntingtin Is Degraded in Lysosomes. (A) Lysosome inhibitor 
BAF causes accumulation of both HTT72Q and LC3-II in the cells expressing HTT72Q. 
(B, C) HTT72Q aggregates co-localize with LAMP2-labelled lysosomes (red) in cells 
stably expressing HTT72Q and transiently expressing Flag-HDAC4 in the absence (Ctrl) 
or presence of BAF. Representative fluorescent images (B) are shown and white arrows 
indicate HTT72Q aggregates that co-localize with LAMP2. The plot (C) shows the 
percentage of HTT72Q aggregates associated with LAMP2-labelled lysosomes to total 
aggregates in Ctrl or BAF-treated cells. 
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HDAC4 Inhibits MAP1S-mediated Autophagic Clearance of Mutant Huntingtin 
Aggregates 
As discussed in chapter II, HDAC4 suppresses autophagy through MAP1S. 
HDAC4 binds to and deacetylates MAP1S, which leads to MAP1S destabilization and 
further inhibits MAP1S-mediated autophagy. To study the role of HDAC4 in regulating 
autophagic turnover of mHTT aggregates, the interaction between HDAC4 and MAP1S 
was further examined in N2α cells (Figure 13A) and brain tissue lysates from wild-type 
or MAP1S-/- mice (Figure 13B). In addition, suppression of MAP1S with specific siRNA 
in the HeLa cells stably expressing GFP-HTT72Q led to inhibition of autophagic flux 
(Figure 13C, D). Consequently, autophagy defects induced by silencing MAP1S caused 
accumulation of GFP-HTT72Q aggregates (Figure 13E, F). Accumulation of GFP-
HTT74Q was also observed in MAP1S-/- MEF cells transiently overexpressing GFP-
HTT74Q. The MAP1S-deficiency-triggered accumulation of HTT74Q aggregates was 
confirmed when the same cell lysates were analyzed by AGERA (Figure 13G-I). 
Enhancement of mHTT aggregation by overexpression of HDAC4 was only observed in 
wild-type but not MAP1S-/- MEF cells (Figure 13J, K). These results indicate that 
HDAC4-mediated suppression of autophagic degradation of mHTT aggregates is 
MAP1S-dependent. 
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Figure 13. HDAC4 Inhibits MAP1S-mediated Autophagic Clearance of Mutant 
Huntingtin Aggregates. (A, B) Endogenous HDAC4 interacts with MAP1S. Lysates of 
N2α cells (A) or brain tissues of wild-type (+/+) and MAP1S-/- mice (B) were precipitated 
with specific antibodies against HDAC4 or MAP1S, or IgG control. (C, D) MAP1S 
suppression with siRNA reduces levels of LC3-II in cells stably expressing HTT72Q in 
the absence (Ctrl) or presence of BAF. Representative immunoblot analyses (C) and 
quantification (D) are shown. (E, F) Suppression of MAP1S with siRNA increases 
levels of HTT72Q aggregates in cells stably expressing HTT72Q. Representative 
immunoblot results (E) and quantification (F) are shown. (G-I) Depletion of MAP1S 
increases levels of HTT74Q aggregates in wild-type and MAP1S-/- MEF cells transiently 
expressing HTT74Q. Representative immunoblot results (G, H) and quantification (I) of 
levels of HTT74Q aggregates in wild-type and MAP1S-/- MEF cells analyzed by 
stacking gel electrophoresis (G) or AGERE (H) are shown. (J, K) MAP1S is required 
for the HDAC4-dependent increase in levels of HTT74Q aggregates. Representative 
immunoblot results (J) and quantification (K) of the differences between wild-type and 
MAP1S-/- MEF cells are shown. 
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Figure 13. Continued. 
HDAC4 Interacts with MAP1S via an HDAC4-binding Domain (HBD) 
Full length MAP1S (FL) is processed by post-translational modification to 
multiple isoforms that include heavy chain (HC), short chain (SC) and light chain (LC) 
(Figure 14A) (38,41,54). Association of HDAC4 with MAP1S HC and SC products in 
addition to FL was apparent (Figure 14B), which suggested that a domain localized 
between R653 and Q855 (Figure 14A), the overlapping region between the HC and SC, 
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Figure 14. MAP1S Interacts with HDAC4 via an HDAC4-binding Domain (HBD) 
in the Overlapping Region between the Heavy Chain (HC) and Short Chain (SC) of 
MAP1S. (A) A diagram shows the sequence domains of MAP1S protein. FL, full length; 
HC, heavy chain; SC, short chain; LC, light chain; 4G1, region recognized by MAP1S 
monoclonal antibody; HBD, HDAC4-binding domain with the R653-Q855 fragment. All 
sequence numbers were deduced based only on experiment results. (B) HDAC4 interacts 
with MAP1S isoforms SC, HC, and FL. Lysates of 293T cells overexpressing HDAC4 
and HA-fused MAP1S isoforms were precipitated with MAP1S-specific antibodies or 
IgG control. (C) HDAC4 interacts with MAP1S SC but not LC. Lysates of 293T cells 
overexpressing HDAC4 and HA-fused MAP1S SC or LC were precipitated with HA-
specific antibodies or IgG control. (D, E) HDAC4 binds with GST-SC but not GST-LC. 
GSH beads bound with purified GST-fused MAP1S SC, but not LC (E) pulled down 
HDAC4 in cell lysates (D). HDAC4 was revealed on immunoblots with specific 
antibodies and GST fusion proteins were visualized with coomassie blue staining. (F) 
HDAC4 interacts with an overlapping domain between MAP1S HC and SC. Lysates of 
293T cells overexpressing HDAC4 and HA-fused MAP1S sequence R653-Q855 (HA-
HBD) were immunoprecipitated with HA-specific antibodies or IgG control and 
immunoblotted with HA or MAP1S-specific antibodies. (G) The interaction between 
MAP1S and HDAC4 is abolished when the HBD is deleted. Lysates of 293T cells 
overexpressing HDAC4 and HA-fused full length MAP1S (HA-FL) or mutant MAP1S 
with sequence R653-Q855 deleted (HA-HBDΔ) were precipitated with HA- or HDAC4-
specific antibodies or IgG control and blotted with antibodies against HA and HDAC4. 
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Figure 14. Continued. 
was necessary and sufficient for the interaction between HDAC4 and MAP1S. MAP1S 
LC, lacking the sequence R652-Q855, exhibited no interaction with HDAC4 (Figure 
14C). The isoform-specific interaction was further confirmed using purified MAP1S SC 
or LC variants tagged with glutathione S-transferase (GST) (GST-SC or GST-LC) to 
pull down HDAC4 from lysates of 293T cells overexpressing HDAC4. Notably, GST-
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SC pulled down HDAC4, but GST-LC did not (Figure 14D, E). Immunoprecipitation by 
using HA-tagged R653-Q855 fragment (HA-HBD) alone further indicated HBD 
localized within the fragment (Figure 14F). Deletion of HBD in MAP1S led to the 
abolishment of its interaction with HDAC4 (Figure 14G). All the results indicate that 
MAP1S interacts with HDAC4 within cells and the interaction occurs through HBD. 
Overexpression of HBD Promotes Autophagy by Sustaining MAP1S Level 
To further confirm that the impact of HDAC4 on autophagy is specifically 
through its association with MAP1S, the impact of HBD and HBDΔ on MAP1S-
mediated autophagy was first examined. When either HBD or HBDΔ was overexpressed 
in HeLa cells, HBD but not HBDΔ reduced the amount of MAP1S co-precipitated with 
HDAC4 (Figure 15A, B), suggesting that HBD competed with full length MAP1S for 
binding with HDAC4. In addition, the stability of endogenous MAP1S was examined 
when cells were overexpressed with either HBD or HBDΔ. The results showed that 
overexpression of HBD but not HBDΔ enhanced the stability of endogenous MAP1S 
(Figure 15C, D), and only overexpression of HBD increased levels of endogenous 
MAP1S protein (Figure 15E, F). Consequently, autophagic flux represented by levels of 
LC3-II in the presence of BAF was enhanced by overexpression of HBD but not HBDΔ; 
and such enhancive effect was only observed in the presence of endogenous MAP1S 
(Figure 15E, G). HDAC4 overexpression-induced decrease in levels of MAP1S was 
abolished when cells were overexpressed with HBD but not HBDΔ (Figure 15H, I). 
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Figure 15. Overexpression of HBD Interrupts HDAC4-MAP1S Interaction, 
Activates MAP1S-mediated Autophagy. (A, B) Overexpression of HBD but not HA‐
HBD∆ reduces HDAC4‐bound MAP1S. Equal amounts of lysates collected from HeLa 
cells expressing control HA vector, HA-HBD or HA‐HBD∆ were subjected to 
immunoprecipitation with HDAC4‐specific antibodies. Representative immunoblot 
results (A) and quantification of the precipitated MAP1S (B) are shown. (C, D) 
Overexpression of HBD but not HBD∆ enhances the stability of endogenous MAP1S in 
HeLa cells. Lysates of HeLa cells transiently transfected with HA vector, HA‐HBD or 
HA‐HBD∆ were collected at different time after 10 µg/ml cycloheximide treatment. 
Representative immunoblot results (C) and quantification (D) are shown. (E‐G) 
Overexpression of HBD but not HBD∆ enhances autophagic flux in the presence of 
MAP1S. Lysates were collected from wild-type or MAP1S-/- HeLa cells transiently 
transfected with HA vector, HA‐HBD or HA‐HBD∆ in the absence (Ctrl) or presence of 
BAF. Representative immunoblot results (E) and quantification of relative levels of 
MAP1S in wild-type cells in the absence of BAF (F) or relative levels of LC3‐II in the 
presence of BAF (G) are shown. (H-J) Overexpression of HBD but not HBD∆ prevents 
HDAC4‐induced destabilization of MAP1S and suppression of autophagic flux. Lysates 
were collected from HeLa cells transiently co‐transfected with HDAC4 and HA vector, 
HA‐HBD or HA‐HBD∆ in the absence (Ctrl) or presence of BAF. Representative 
immunoblot results (H) and quantification of relative levels of MAP1S in the absence of 
BAF (I) or LC3‐II in the presence of BAF (J) are shown. 
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Figure 15. Continued. 
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HDAC4 overexpression-induced impairment of autophagic flux was inhibited when cells 
were overexpressed with HBD but not HBDΔ (Figure 15H, J). 
Overexpression of HBD Enhances Levels of MAP1S and Alleviates HDAC4-induced 
Mutant Huntingtin Aggregation 
To study the impact of HBD on HDAC4-induced mHTT aggregation, HBD or 
HBD∆ were overexpressed in the N2α cells co-overexpressed with GFP-HTT74Q.  
Overexpression of HBD but not HBD∆ sustained levels of endogenous MAP1S and led 
to significant decrease in levels of mHTT aggregates (Figure 16A-C). In addition, 
overexpression of HBD but not HBD∆ protected the stability of endogenous MAP1S 
when the cells were simultaneously overexpressed with HDAC4, and inhibited HDAC4-
induced accumulation of mHTT aggregates (Figure 16A-C). These results suggest that 
the interaction between HDAC4 and MAP1S is required for HDAC4 to exert 
suppressive effect on MAP1S-mediated autophagic turnover of mHTT aggregates. 
Therefore, the HBD interrupts MAP1S-HDAC4 interaction and promotes MAP1S-
mediated autophagic clearance of mHTT aggregates.  
A diagram shows the potential mechanism by which HDAC4 regulates MAP1S-
mediated autophagic turnover of mHTT aggregates (Figure 17). Under normal condition, 
isolation membrane‐associated acetylated-MAP1S is deacetylated and destabilized by 
microtubule or aggregate‐associated HDAC4. In the presence of excessive HBD, HBD 
competes with acetylated MAP1S for interaction with HDAC4, which leads to the 
exposure of mHTT aggregates to be packaged by the MAP1S‐associated isolation 
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Figure 16. Overexpression of HBD Alleviates HDAC4-induced Mutant Huntingtin 
Aggregation. (A-C) Overexpression of HBD but not HBD∆ reduces levels of HTT74Q 
aggregates. N2α cells transiently expressing GFP‐HTT74Q were simultaneously 
transfected with two additional plasmids with one to express HA control, HA-HBD or 
HA-HBD∆, and another to express control or HDAC4, respectively. Representative 
immunoblot results of HTT74Q resolved by stacking gel or AGERA (A) and the 
respective quantification in stack gel (B) or AGERA (C) are shown. 
membrane. Autophagosomes that contain mHTT aggregates associate with microtubules 
through acetylated MAP1S and fuse with lysosome to become autolysosomes in which 
mHTT aggregates are degraded by lysosomal enzymes (20). 
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Figure 17. Potential Mechanism of HDAC4 in MAP1S-mediated Autophagic 


















































































































Wild-type Huntingtin (HTT) is a large protein consisted of about 3,144 amino 
acids, widely distributed but most concentrated in the neurons (99) (100). Wild-type 
HTT contains a 6-35 glutamine-repeats region that is also called polyglutamine (ployQ) 
region in the N-terminus of the protein. Mutant HTT is the protein that has a ployQ 
expansion longer than 36 residues and forms insoluble aggregates that are toxic to the 
neurons and cause Huntington’s disease (HD) (101). Although there is no efficient 
treatment that has been developed specifically for this devastating disease, enhancing 
clearance of mHTT aggregates is considered as one of the feasible approaches to slow 
down the neurodegeneration in HD and has revealed some beneficial effects in animal 
models (20,102). 
Recently, HDAC4 reduction is identified as a potential treatment to target mHTT 
aggregates in the HD mouse model (93). The mechanistic study suggests HDAC4 
regulates mHTT in ways different from transcriptional regulation, as deletion of HDAC4 
in mouse brain has no effect on histone acetylation profiles and global transcription 
(103).  In our study, we decipher the mechanism that HDAC4 induces mHTT 
aggregation by suppressing MAP1S-mediated autophagy. HDAC4 associates with and 
forms shells surrounding mHTT aggregates in the cytoplasm (20,93). HDAC4 directly 
interacts with the autophagy activator MAP1S, reduces the stability of MAP1S protein, 
consequently suppresses the autophagic flux mediated by MAP1S, and impairs the 
degradation of mHTT aggregates.  
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Wild-type HTT plays important roles during embryogenesis and brain 
development (104). It can not only interact with microtubules and regulate vesicle 
trafficking (105-107), but also bind to transcription factors to modulate gene expression 
in neurons (108). In addition, both in vitro and in vivo studies indicate wild-type HTT 
can disrupt the activation of caspases to execute apoptosis (109). The homology between 
regions of HTT and the yeast autophagy regulatory proteins predicts a normal regulatory 
function in autophagy (110). Recent studies also suggest an essential role of wild-type 
HTT in autophagy as a scaffold protein (23,111). Importantly, HDAC4 only interacts 
with aggregate-prone mHTT that has long ployQ stretches but not with wild-type HTT 
(93). Thus, HDAC4 and MAP1S-mediated autophagic clearance does not affect wild-
type HTT and its cellular functions. 
In this study, we define the role of MAP1S in the HD development through its 
function in multiple steps of autophagy. Our results show that it is the inhibition of 
HDAC4 and its associated deacetylase activity that enhances the stability of MAP1S, 
increases autophagic flux and improves clearance of mHTT aggregates. The mHTT 
disrupts the wild-type HTT-mediated regulation of autophagosomal dynamics and 
causes defects in cargo degradation (112). We reason that soluble mHTT protein may 
function similar as wild-type HTT in association with motor protein complexes on 
microtubules. However, mHTT sequesters HDAC4 on microtubules, which further 
impairs the stability and microtubule-associated functions of MAP1S through HDAC4-
induced deacetylation and consequently interrupts autophagic flux. This defect leads to 
accumulation of mHTT and consequent formation of mHTT aggregates. The mHTT 
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aggregates further sequester HDAC4 that protects the aggregates from degradation by 
MAP1S-mediated autophagy (20). 
HDACs facilitate the removal of acetyl groups during epigenetic regulation, 
which results in transcriptional repression. Because high expression levels or 
hyperactiviton of multiple HDACs are the mechanisms that promote epigenetic 
dysregulation in cancer (113), HDACs emerge as a druggable class of enzymes in cancer 
treatment. Disruption of HDAC activity with HDAC inhibitors (HDACi) shows 
pleiotropic effects in cancer cells in pharmacodynamics studies in that HDACi may also 
exhibit effects on neurodegeneration (113,114). However, several studies show that pan-
HDACi is unsuitable for treating HD, as genetic knockdown of HDAC3 or HDAC7, or 
knockout of HDAC6 has no effects on ameliorating HD in mouse model (115-118). 
Consistent with the result that genetic knockout of HDAC4 in mouse delays cytosolic 
mHTT aggregation and improves motor coordination, neurological phenotypes and 
longevity (93), our study shows that inhibition of HDAC4 with specific siRNA results in 
stabilization of MAP1S protein, activation of MAP1S-mediated autophagic flux and fast 
degradation of mHTT (20). This provides a mechanism by which therapeutic reduction 
of HDAC4-associated activity can reduce accumulation of cytoplasmic mHTT 
aggregates and alleviate neurodegeneration (20). 
Since a series of cellular processes are regulated by HDAC4, any small molecule 
inhibitor of HDAC4 will inhibit the general activity of HDAC4 and is surely expected to 
cause unnecessary side effects besides the clearance of mHTT aggregates. Here we have 
identified an HDAC4-binding domain (HBD) from MAP1S, which is the overlapping 
67 
region between the heavy chain (HC) and short chain (SC) of MAP1S. HBD specifically 
interrupts HDAC4-MAP1S interaction and protects MAP1S from being deacetylated by 
HDAC4-associated deacetylase activity. Since the approach of HIV TAT-mediated 
protein transduction is widely utilized, TAT-tagged HBD can be first synthesized to 
directly validate its biological effects on autophagy in vitro and in vivo. Further 
development of short peptides to disrupt the interaction between HDAC4 and MAP1S 
may specifically enhance the MAP1S-mediated autophagic clearance of mHTT 
aggregates (20). 
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CHAPTER IV  
SPERMIDINE ACTIVATES MAP1S-MEDIATED AUTOPHAGY TO PROLONG 
LIFESPANS AND SUPPRESS DIETHYLNITROSAMINE-INDUCED 
HEPATOCARCINOGENESIS 
Introduction 
Hepatocellular carcinoma (HCC) is the primary malignancy of the liver caused 
by long-term hepatic injuries. Due to late-diagnosis and few effective drugs available, 
HCC is a leading cause of cancer mortality worldwide (25). The incidence and mortality 
rate of HCC also rise dramatically in recent decades in the United States (26,27). Only 
small portions of HCC patients with early diagnosis may be treated with surgery or liver 
transplantation, but have poor prognosis (30). Though it is an FDA approved drug for 
advanced HCC, Sorafenib has severe toxicity and only extends survival for 3 months 
(119). Prescribed medications such as statins, metformin and aspirin have shown 
chemopreventive effects for HCC, but each simultaneously exhibits other unintended 
effects (30). Thus, development of therapeutics and effective prevention approach for 
HCC is in urgent need.  
Several experimental animal models have been developed to investigate the 
pathogenesis of HCC and the potential treatment for HCC (120). There are three types of 
mouse models to study HCC currently based on the mechanism of how HCC is triggered, 
including chemical-induced HCC mouse models, genetically modified HCC mouse 
models and xenograft models. Diethylnitrosamine (DEN)-induced HCC mouse model is 
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one of the most commonly used models to define HCC pathogenesis. A single injection 
of DEN in 15-day-old male mice leads to tumor development in a dose-dependent 
manner (120,121). DEN induces genomic instability via DNA alkylation mediated by 
cytochrome P450 which is most activated in the centrilobular hepatocytes. In addition, 
DEN induces cellular oxidative stress which further contributes to hepatocellular 
carcinogenesis (122). High incidence of HCC in developing countries is in partially due 
to the consumption of food contaminated with Aspergillus fungi which produce aflatoxin 
B1 (AFB) (25). Thus, AFB is another frequently used carcinogen to induce HCC in mice. 
Carbon tetrachloride (CCl4) exposure induces hepatic injuries associated with a series of 
inflammatory responses which result in liver fibrosis and ultimately HCC (120). 
Therefore, CCl4-treated mice develop HCC in a context of liver fibrosis. Since viral 
infection is a main cause of HCC, transgenic mouse models expressing viral genes are 
generated to study the pathogenesis of HCC involved with Hepatitis B (HBV) and 
Hepatitis C (HCV). Besides, several HCC mouse models are established by 
overexpression of specific oncogenes, such as c-myc and β-catenin (123,124). Xenograft 
mouse models are generated by injecting HCC cell lines in immune deficient mice to 
develop HCC and are usually used for drug screening (120). 
Autophagy is the primary mechanism for removal of misfolded proteins, 
aggresomes and dysfunctional organelles through lysosomal degradation, and further 
reduces cellular oxidative stress to suppress accumulation of cellular damages, which is 
the common underlying process for aging and cancers (3,125). Autophagy has essential 
roles in lifespan extension. Calorie restriction (CR) and pharmacologic intervention that 
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regulates growth-related signaling or anti-aging pathways can prolong lifespans by 
enhancing autophagy activity (17). In addition to aging, autophagy suppresses 
tumorigenesis by alleviating levels of cellular oxidative stress which further induces 
genomic instability and tumorigenesis (15). Impaired autophagy results in tumor 
initiation and development (32,33), and leads to shortened lifespans in cancer patients as 
well (34-36). Therefore, elevating autophagy activity may be utilized to prevent and treat 
HCC. Induction of autophagy by pharmacologic agents has attracted enormous attention 
for cancer prevention. 
Microtubule-associated protein 1 small form (MAP1S) associates with 
microtubules stabilized by either chemotherapeutic drug and microtubule stabilizer 
taxanes or tumor suppressive protein Ras-association domain family 1 isoform A 
(RASSF1A) (38,54). Specific accumulation of MAP1S short chain (SC) responding to 
mitotic arrest leads to mitochondrial collapse on mitotic spindle and mitotic cell death 
(40). Importantly, MAP1S has been identified as a novel autophagy activator. The 
association of MAP1S with microtubule and LC3 promotes autophagosome formation 
and transportation. Meanwhile, MAP1S regulates autophagy initiation through Bcl-2 and 
P27 (41). Autophagy defects caused by MAP1S depletion lead to enhancement of 
cellular oxidative stress, liver sinusoidal dilation and fibronectin-induced liver fibrosis, 
and reduction in mouse lifespans (4). In DEN-induced HCC mouse model, MAP1S 
suppresses tumor initiation and development through autophagy regulation (33). In the 
early stage of tumorigenesis, DEN treatment leads to immediate elevation in levels of 
MAP1S protein to activate autophagic turnover of P62-associated aggresomes and 
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inhibit DNA double-strand breaks (DSB) induced by accumulated oxidative stress. 
MAP1S is also maintained in high levels in tumor foci to accelerate autophagy and 
prevent genomic instability during tumor development (15,33). In addition, clinical 
evidence suggests that higher levels of MAP1S in tumor tissues predict longer survival 
for cancer patients (35,36). Thus, elevating levels of MAP1S can activate autophagic 
flux to extend lifespans and suppress tumorigenesis. 
Spermidine is a polyamine originally isolated from semen and also enriched in 
wheat germ, citrus fruits, and soybeans (52). It has been recently characterized as a 
longevity enhancer through induction of autophagy in multiple model systems (51). 
However, the mechanism by which spermidine induces autophagy remains mysteries of 
molecular biology, though previous studies suggest that a combination of transcription-
dependent and independent regulatory events may be involved (53,126). 
Acetylproteomic analyses indicate spermidine alters the acetylation status of multiple 
autophagy-relevant proteins including MAP1S (127). Notably, spermidine enhances 
levels of acetylated MAP1S by 24-fold in cytoplasm, which encourages us to further 
characterize the molecular mechanism of how spermidine elevates the acetylation of 
MAP1S. As discussed in chapter II, HDAC4 negatively regulates MAP1S through 
deacetylation, which also prompts us to study the roles of HDAC4 and MAP1S in 
spermidine-induced autophagy. In addition, the impact of spermidine-induced lifespan 
extension needs further study on mammals, and the role of spermidine in tumor 
suppression is still unknown. Elucidating the molecular mechanism of spermidine-
induced autophagy and defining the effects of spermidine on aging and tumorigenesis 
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can provide insights on the drug development for lifespan extension and cancer 
treatment. 
Herein, we discover that spermidine-induced autophagy depends on MAP1S and 
is mediated by MAP1S-HDAC4 complex. Spermidine increases the acetylation and 
stability of MAP1S protein by suppressing cytosolic HDAC4. Spermidine 
dephosphorylates HDAC4 on serine 246 and serine 632 residues, leading to the release 
of HDAC4 from its cytoplasmic partner 14-3-3 and nuclear import of HDAC4. 
Spermidine-induced HDAC4 nuclear translocation further results in the dissociation of 
MAP1S from HDAC4 to maintain its acetylation and protein stability. Lysine 520 
residue of MAP1S, the spermidine-induced acetylation site, facilitates autophagosome-
lysosome fusion and is critical in spermidine-induced autophagy. In vivo results also 
indicate that spermidine activates MAP1S-mediated autophagic flux to prolong lifespans 
and suppress DEN-induced HCC in wild-type mice. The suppressive roles of spermidine 
in aging and HCC is abolished in MAP1S-/- mice, suggesting the presence of MAP1S is 
essential in spermidine-induced lifespan extension and tumor suppression. 
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Materials and Methods 
Animals 
Animal protocols were approved by the Institutional Animal Care and Use 
Committee (IACUC), Institute of Biosciences and Technology, Texas A&M Health 
Science Center. All animals received human care according to the criteria outlined in the 
‘Guide for the Care and Use of Laboratory Animals’ prepared by the National Academy 
of Sciences and published by the National Institutes of Health (NIH publication 86-23 
revised 1985). C57BL/6 wild-type and MAP1S-/- mice were bred and genotyped as 
previously described (41). Mice were fed with drinking water or water containing 3 mM 
spermidine (Sigma, #S4139) and were observed to record survival times when found to 
be moribund. Diethylnitrosamine (DEN) (Sigma, #0756) was used to induce 
hepatocellular carcinogenesis in mice as previously described (33). A single 
intraperitoneal administration of 10 µg/g body weight of DEN dissolved in saline was 
applied to 15-day-old wild-type and MAP1S-depleted male littermates. Mice were 
sacrificed with euthanasia techniques at 7 months after birth. The body weight, liver 
weight, and the ratio of liver weight to body weight were recorded. Liver tissues were 
frozen or fixed for further analyses.   
 
Cell Culture 
Most cell lines, including HeLa, HepG2, HEK-293T, HeLa-RFP-LC3 cells, and 
MEF cells, were cultured in the DMEM culture media containing 10% FBS and 
antibiotics. Primary mouse hepatocytes were grown in William’s E culture media with 
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10% FBS, ITS-G and 100 nM dexamethasone. PBS and 0.25% trypsin were used for 
subculture.  
Cell Transfection 
Cell lines used for transfection included HeLa, HEK-293T, HeLa-RFP-LC3 cells, 
and MEF cells. For transient knockdown experiments, cells were cultured at 30% 
confluence on the cell culture plates or coverslips and transfected with negative control 
siRNA or specific siRNA by Oligofectamine according to the manufacturer’s 
recommended instruction. For transient overexpression experiments in HeLa, HeLa-
RFP-LC3 cells, and MEF cells, cells were cultured at 70% confluence on the cell culture 
plates or coverslips and transfected with control vector or plasmids encoding specific 
genes by Lipofectamine 2000 according to the manufacturer’s recommended instruction. 
For transient overexpression in HEK-293T cells, cells were cultured at 60% confluence 
on the cell culture plates and transfected with control vector or plasmids encoding 
specific genes by using calcium phosphate transfection kit according to the 
manufacturer’s recommended instruction. 
Fluorescence Microscopy 
HeLa-RFP-LC3 cells were treated with 100 µM spermidine, or 10 nM BAF for 4 
hours before fixation. Cells were fixed with 4% (w/v) paraformaldehyde in PBS at room 
temperature for 30 minutes and processed for fluorescence microscopy analyses. HeLa 
cells or MEF cells transfected with plasmids encoding GFP or GFP-HDAC4 were 
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treated with 100 µM spermidine for 4 hours before fixation. Cells were fixed with 4% 
(w/v) paraformaldehyde in PBS at room temperature for 30 minutes, stained DNA with 
TO-PRO-3 (Invitrogen, #T3605) for 5 minutes and processed for fluorescence 
microscopy analyses. HeLa or HeLa-RFP-LC3 cells were transfected with the plasmids 
expressing HA-MAP1S, or HA-MAP1S K520R. HeLa cells transfected with the 
plasmids expressing GFP-HDAC4 and HA-MAP1S were treated with 100 µM 
spermidine for 4 hours. Cells were fixed with 4% (w/v) paraformaldehyde in PBS at 
room temperature for 30 minutes and then permeabilized with 0.1% Triton X-100 in 
PBS for 20 minutes. Cells were blocked with 1% BSA in PBS for 20 minutes, and then 
incubated with primary antibodies against HDAC4, LAMP2, HA-tag (Covance, #MMS-
101P, dilution 1:1000) for 1 hour at room temperature, and the corresponding rhodamine 
or alexa fluor 488 (Invitrogen, #A21206, #A21202, dilution 1:400)-conjugated 
secondary antibodies for 1 hour at room temperature for fluorescence microscopy 
analyses. Images were captured with a Zeiss LSM 510 Meta Confocal Microscope. The 
number of RFP-LC3 punctate foci on each image was calculated and lysosome-
associated RFP-LC3 punctate foci were analyzed using ImageJ software. 
 
Cell Fractionation 
Cells were seeded in 10 cm culture dishes and treated with 100 µM spermidine 
for 4 hours. Cell pellets were collected after centrifugation at 6,000 rpm for 5 minutes 
and resuspended in five times of volume of cytoplasmic extract (CE) buffer (10 mM 
HEPES, pH 7.9, 10 mM KCl, 0.1 M EDTA) containing 0.3% NP-40 and protease 
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inhibitor cocktails for 5 minutes 4 °C. Cells were lysed with vortex all the time. The 
cytoplasmic extracts were the supernatants that collected after centrifugation at 3,000 
rpm for 5 minutes at 4 °C. The pellets were washed by centrifugation in CE buffer 
without NP-40 twice, and resuspended in equal volume of nuclear extract (NE) buffer 
(20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 25% Glycerol) containing protease 
inhibitor cocktails on ice for 10 minutes. Nuclear fraction was further lysed with vortex 
all the time. The nuclear extracts were the supernatants collected after centrifugation at 
14,000 rpm for 5 minutes at 4 °C. The cytoplasmic and nuclear extracts were further 
processed for immunoblot analyses. 
Immunoblot Analyses 
Cells were lysed in the cell lysis buffer with 1mM PMSF on ice for 30 minutes. 
The total protein concentration of the cell lysates was determined by using BCA protein 
assay kit. The cell lysates were then mixed with SDS loading buffer and boiled for 10 
minutes. Cell lysates were loaded on SDS-polyacrylamide gels containing 8, 10, 12 or 
15% (w/v) acrylamide. Proteins were separated by electrophoresis, transferred on to 
PVDF membranes. The membranes were blocked with 5% (w/v) non-fat milk in TBST 
for 1 hour at room temperature, bound with primary antibodies overnight at 4 °C and 
incubated with HRP-conjugated secondary antibodies for 2 hours at room temperature. 
Proteins were detected by ECL Prime Western Blotting Detection Reagents. The 
exposed X-ray films were processed using developer and fixer, scanned into image files. 
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The relative intensity of a band to internal control was measured using ImageJ software. 
The catalog numbers and dilutions of primary antibodies are listed in the Table 4. 
 




To analyze levels of acetylated MAP1S by immunoprecipitation, cell lysates 
were prepared by using RIPA buffer with 1 mM PMSF, protease inhibitor cocktails, 5 
mM NAM and 10 µM TSA; and centrifuged at 14,000 rpm for 15 minutes at 4 °C to 
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isolate the supernatants. Lysates of same amount of total proteins were mixed with 30 µl 
anti-acetyl-lysine agarose conjugate overnight at 4 °C for precipitation of total acetylated 
lysine proteins.  
To study the interaction between HDAC4 and MAP1S or 14-3-3 by 
immunoprecipitation, cell lysates were prepared by using NP-40 buffer with 1mM 
PMSF and protease inhibitor cocktails. The supernatants were collected after 
centrifugation at 14,000 rpm for 15 minutes at 4 °C. Same amount of lysates with 1.5 mg 
of total protein were subjected to immunoprecipitation with 2 µg antibodies against 
MAP1S, HDAC4, HA, or the respective IgG control, and incubated with 30 µl Protein 
G-Sepharose beads. After overnight rotation at 4 °C, beads that binds with antibodies 
and the bound proteins were precipitated and washed extensively with the NP-40 buffer 
four times. The final precipitates were resuspended in 100 µl lysis buffer containing SDS 
loading buffer and boiled for 10 minutes for further immunoblot analyses.  
 
Protein Half-life Measurement 
MEF cells were seeded in 35 mm culture dishes and treated with 100 µM 
spermidine. After 4 hours of spermidine treatment, the protein synthesis inhibitor 10 
µg/ml CHX was added into the culture media. Cell lysates were harvested at the 
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Site-directed Mutagenesis 
HA-MAP1S K520R mutation was introduced into the full length HA-MAP1S 
using QuikChange II kit (Agilent Technologies, #200523), according to the 
manufacturer’s recommended instruction. HA-MAP1S K520R was PCR amplified from 
HA-MAP1S template with primers (5’-CTCCCGGGGGGTCCTGGCTTCTTTCTC-3’, 
5’-GAGGAAAGAAGCCAGGACCCCCCGGGAG-3’). The restriction enzyme DpnI 
was then added into the mixture after PCR reaction for digesting the template of full 
length HA-MAP1S. After transformation, the positive colonies were picked and verified 
by DNA sequencing.  
 
Dihydroethidium (DHE) Staining 
A part of frozen samples was cryosectioned and used for measurement of 
oxidative stress. As previously described (4), the cryosections were stained with 2 mM 
dihydroethidium hydrochloride (Invitrogen, #D-1168) for 30 minutes at 37 °C. DHE 
permeates into cells and reacts with reactive oxygen species (ROS). The products of 
DHE and cytosolic superoxide intercalate into genomic DNA upon oxidation, and label 
nuclear with red fluorescent signals monitored by fluorescence microscopy analyses. 
The intensities of red fluorescent signals were quantified by ImageJ software. 
 
Histology 
Paraffin sections were re-hydrated for hematoxylin (Fisher Scientific, #SH26) 
and eosin (Sigma, #HT110116) (H&E) staining. The area of sinusoidal space was 
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quantified using ImageJ software. For immunohistochemistry staining, slides were 
boiled in citrate buffer (10 mM sodium citrate, 0.05% Tween-20), pH 8.0 for 20 minutes 
for antigen retrieval after re-hydration. Slides were further processed and stained with γ-
H2AX (Cell Signaling, #9718, dilution 1:480) using HRP/ 3, 3’-Diaminobenzidine 
(DAB) detection IHC kit (Abcam, #64261) according to manufacturer’s recommended 
instruction. The nuclei were counter stained with hematoxylin. Positive staining of γ-
H2AX was measured by ImageJ software. 
Statistical Analyses 
Statistical significance was determined by Student’s t-test, with significance set 
to *, p≤0.05; **, P≤0.01; and ***, P≤0.001. Error bars indicate standard deviation. The 
overall survival and median survival were analyzed by the Kaplan-Meier method. Cox 




Spermidine Enhances MAP1S Protein Level and Accelerates Autophagic Flux 
To study the impact of spermidine on autophagic flux, MEF or HeLa cells were 
first treated with spermidine for different amount of time or different concentrations of 
spermidine. Increased levels of MAP1S as well as autophagy marker LC3-II in a time 
and dose-dependent manner were observed when cells were treated with spermidine 
(Figure 18A, B). Levels of LC3-II in the presence of lysosome inhibitor BAF were 
elevated upon exposure to 100 µM spermidine for 4 hours (Figure 18C, D), suggesting 
that spermidine accelerated autophagic flux. Meanwhile, HeLa cells stably expressing 
RFP-LC3 were utilized to determine the impact of spermidine on autophagic flux. 
Accumulation of RFP-LC3 punctate foci induced by spermidine treatment, in the 
absence or presence of BAF, further confirmed that spermidine induced autophagy 
activation (Figure 18E, F). All the results indicate that spermidine increases levels of 
MAP1S protein and accelerates autophagic flux. 
Spermidine-induced Activation of Autophagic Flux Depends on MAP1S 
To understand the role of MAP1S in spermidine-induced autophagy, levels of 
LC3 were examined in wild-type or MAP1S-/- mice treated with spermidine. Levels of 
MAP1S and LC3-II were increased after spermidine treatment in livers, as well as other 
organs of mice including brain and heart, in wild-type mice with presence of MAP1S 
protein but not MAP1S-/- mice (Figure 19A, B). This suggested that MAP1S might be 
responsible for the impact of spermidine on autophagy. In addition, MEF cells derived 
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Figure 18. Spermidine Accelerates Autophagic Flux. (A, B) Spermidine enhances 
levels of MAP1S and LC3 in a time and dose-dependent manner. Representative 
immunoblot results show levels of MAP1S and LC3 in MEF or HeLa cells treated with 
100 µM spermidine (SPD) for different amount of time (A) or different concentrations of 
spermidine for 4 hours (B). (C, D) Spermidine enhances levels of MAP1S and LC3-II. 
Representative immunoblot results (C) and quantification (D) show the impact of 
spermidine on levels of MAP1S and LC3 in HeLa cells in the absence (None) or 
presence of BAF. (E, F) Spermidine induces accumulation of RFP-LC3 punctate foci. 
Representative fluorescent images (E) and quantification (F) of the number of RFP-LC3 
punctate foci in HeLa cells stably expressing RFP-LC3 untreated (Ctrl) or treated with 
spermidine (SPD) in the absence (None) or presence of BAF. 
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Figure 19. Spermidine-induced Autophagy Depends on MAP1S. (A, B) Spermidine 
enhances levels of LC3-II in wild-type mice but not MAP1S-/- mice. Representative 
immunoblot analyses (A) and quantification (B) show the impact of spermidine on levels 
of LC3-II in organs collected from wild-type or MAP1S-/- mice. (C, D) Spermidine 
enhances levels of LC3 in wild-type but not MAP1S-/- MEFs. Representative 
immunoblot results (C) and quantification (D) show levels of LC3 in MEF cells derived 
from wild-type or MAP1S-/- mice treated with different concentrations of spermidine for 
4 hours. (E, F) Spermidine-induced enhancement in levels of LC3 depends on MAP1S. 
Representative immunoblot results show the impact of spermidine on levels of LC3-II in 
MEF cells (E) or primary mouse hepatocytes (F) isolated from wild-type or MAP1S-/- 
mice in the absence or presence of BAF. 
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from wild-type or MAP1S-/- mice were utilized to confirm the role of MAP1S in 
spermidine-induced autophagy. Similarly to the results in mice, spermidine-induced 
enhancement in levels of LC3-II was also observed in wild-type MEF cells but not 
MAP1S-/- MEF cells (Figure 19C, D). Furthermore, spermidine-induced activation of 
autophagic flux as indicated by levels of LC3-II in the presence of BAF was observed in 
wild-type but not MAP1S-/- MEF cells (Figure 19E) or primary mouse hepatocytes 
(Figure 19F). Therefore, the activation of autophagic flux by spermidine requires the 
presence of MAP1S. 
Spermidine Enhances Acetylation and Stability of MAP1S through HDAC4 
To study the mechanism by which spermidine regulates levels of MAP1S protein, 
levels of acetylated MAP1S acetylation were first examined by immunoprecipitation. 
Consistent with a previous report (127), spermidine significantly increased levels of 
acetylated MAP1S (Figure 20A, B). As discussed in chapter II, acetylation is important 
in regulating the stability of MAP1S protein. Thus, the half-life of MAP1S protein was 
measured after MEF cells were untreated or treated with spermidine. Enhancement of 
MAP1S protein stability was observed after spermidine treatment (Figure 20C, D), 
which confirmed that spermidine enhanced the acetylation and stability of MAP1S 
protein.  
HDAC4 has been identified to regulate the acetylation and protein stability of 
MAP1S in chapter II. To determine whether spermidine regulates the acetylation and 
stability of MAP1S through HDAC4, the interaction between HDAC4 and MAP1S in 
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Figure 20. Spermidine Enhances the Acetylation and Stability of MAP1S Protein 
through HDAC4. (A, B) Spermidine increases levels of acetylated MAP1S. 
Representative immunoblot results (A) and quantification (B) shows the impact of 
spermidine on acetylated MAP1S in MEF cells. Acetylated MAP1S was precipitated 
with anti-acetyl-lysine agarose conjugate and immunoblotted with antibodies against 
MAP1S. (C, D) Spermidine enhances the stability of MAP1S protein. MEF cells were 
treated with spermidine, and protein synthesis was terminated with 10 µg/ml 
cycloheximide (CHX). Cell lysates were collected at indicated time points. 
Representative immunoblot results (C) and quantification (D) are shown. The values of 
t1/2 were the time required for half of MAP1S proteins were degraded. (E) HDAC4 
interacts with MAP1S. Lysates of HepG2 cells were immunoprecipitated with antibodies 
against MAP1S or HDAC4, or the respective IgG control. (F) Spermidine-induced 
enhancement in levels of MAP1S and LC3 requires the presence of HDAC4. 
Representative immunoblot results show the impact of spermidine on levels of MAP1S 
and LC3 in HeLa cells treated with random (Mock) or HDAC4-specific siRNA in the 
absence (Ctrl) or presence of BAF. 
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HepG2 cells was re-confirmed by immunoprecipitation (Figure 20E). Suppression of 
HDAC4 with specific siRNA led to increased levels of MAP1S protein; while 
spermidine failed to further induce autophagy activation in HDAC4-suppressed cells 
(Figure 20F). These results suggest that spermidine enhances the acetylation and 
stability of MAP1S protein to activate autophagic flux through HDAC4. 
 
Lysine 520 Residue of MAP1S Is Critical for MAP1S to Promote Autophagosomal 
Degradation in Spermidine-induced Autophagy 
Lysine 520 residue (K520) of human MAP1S has been identified as the 
acetylation lysine site upon exposure to spermidine in the mass spectrometry analyses 
(127). To explore the role of lysine 520 of MAP1S in spermidine-induced autophagy, a 
point mutation of lysine 520 to arginine was introduced to establish K520R mutant 
MAP1S by site-directed mutagenesis. The K520R mutant MAP1S protein exhibited 
higher levels of expression but lower degrees of interaction with HDAC4 than the wild-
type MAP1S protein, although it distributed in the cytoplasm similarly to the wild-type 
MAP1S (Figure 21A, B).  
To study the impact of lysine 520 of MAP1S on autophagy, cells were 
overexpressed with wild-type or K520R mutant MAP1S in the absence or presence of 
BAF. Overexpression of the K520R mutant resulted in increased levels of LC3-II and 
accumulation of RFP-LC3 punctate foci (Figure 21C-F). Autophagy is a dynamic 
process; increased levels of LC3-II may be a result of activated autophagosomal 
biogenesis or inhibited autophagosomal degradation. Levels of accumulated LC3-II 
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remained intact in cells overexpressed with K520R mutant in the presence of lysosome 
inhibitor BAF (Figure 21C, D), which suggested that K520R mutation inhibited 
autophagosomal degradation rather than autophagosomal biogenesis.  
Figure 21. Mutation of MAP1S Lysine 520 Residue Inhibits Autophagy. (A) K520R 
mutant MAP1S has lower affinity with HDAC4 compared to wild-type MAP1S. Lysates 
of 293T cells transiently expressing HA-fused wild-type or K520R mutant MAP1S were 
precipitated with HA antibodies or IgG control. (B) HDAC4 co-localizes with wild-type 
or K520R mutant MAP1S in HeLa cells. (C-F) MAP1S K520R mutation suppresses 
autophagy degradation. Representative immunoblot results of levels of LC3-II in HeLa 
cells (C) and fluorescent images of RFP-LC3 punctate foci in HeLa cells stably 
expressing RFP-LC3 (E) and the respective quantification (D, F) are shown.  
88 
Figure 21. Continued. 
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Notably, the amount of punctate foci of RFP-LC3 associated with LAMP2-
labeled lysosomes in cells expressing K520R mutant was elevated compared to cells 
expressing wild-type MAP1S (Figure 22A-C). This confirmed that the mutation of 
lysine 520 in MAP1S reduced the efficiency of autophagosome-lysosome fusion, one of 
the functions of MAP1S in autophagy (41). 
To further test whether the impact of spermidine on autophagy depends on lysine 
520 of MAP1S, wild-type or K520R mutant MAP1S was re-expressed in MAP1S-/- MEF 
cells. Spermidine failed to increase levels of LC3-II in MAP1S-/- MEF cells re-expressed 
with vector control in the presence of BAF, which indicated that spermidine-induced 
autophagy was impaired when MAP1S was depleted. Spermidine-induced autophagy 
was only restored in cells re-expressed with wild-type MAP1S but not K520R mutant 
MAP1S (Figure 22D, E), suggesting that lysine 520 residue of MAP1S is important for 
MAP1S to promote autophagosomal degradation in spermidine-induced autophagy. 
90 
Figure 22. Lysine 520 Residue of MAP1S Is Critical in Spermidine-induced 
Autophagy. (A-C) Overexpression of K520R mutant inhibits autophagosome-lysosome 
fusion. HeLa cells stably expressing RFP-LC3 were transfected with wild-type or 
K520R mutant MAP1S. Lysosomes were labeled by staining with anti-LAMP2 
antibodies. Representative fluorescent images (A, B) show lysosome-associated (yellow 
in merge) and lysosome-free RFP-LC3 punctate foci (red spots, some are indicated by 
white arrows). An enlarged view of lysosome-free RFP-LC3 punctate foci from (A) is 
shown (B). Quantification (C) shows the percentages of lysosome-free to total RFP-LC3 
punctate foci. (D, E) Wild-type but not K520R mutant MAP1S restores spermidine-
induced autophagy in MAP1S-/- MEF cells. Representative immunoblot results (D) and 
quantification (E) show the impact of spermidine on levels of LC3 in MAP1S-/- MEF 
cells re-expressed with HA, or HA-fused wild-type or K520R mutant MAP1S. 
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Figure 22. Continued. 
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Spermidine Dephosphorylates and Suppresses Cytosolic HDAC4 
To test whether spermidine enhances the acetylation of MAP1S by negatively 
regulating HDAC4, MEF or HeLa cells were treated with different concentrations of 
spermidine for 4 hours. Unexpectedly, spermidine increases levels of HDAC4 protein in 
both cell lines (Figure 23A, B), as well as in different organs of mice (Figure 23C).  
Figure 23. Spermidine Enhances Levels of HDAC4 Protein. (A-C) Spermidine 
increases levels of HDAC4. Represent immunoblot results show levels of HDAC4 in 
MEF (A) or HeLa (B) cells treated with different concentrations of spermidine for 4 
hours, or in organs form 3 pairs of wild-type mice treated with spermidine (C). 
Furthermore, HeLa or MEF cells transiently overexpressed with GFP-HDAC4 
were utilized to monitor the subcellular distribution of HDAC4 after spermidine 
treatment. Although HDAC4 was overexpressed, spermidine enhanced the nuclear 
translocation of HDAC4 in different types of cells (Figure 24A-D); and the actual levels 
of cytosolic HDAC4 were reduced after spermidine treatment (Figure 24E, F). Therefore, 
spermidine causes depletion of cytosolic HDAC4. 
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Figure 24. Spermidine Suppresses Cytosolic HDAC4. (A-D) Spermidine induces the 
nuclear translocation of HDAC4. Represent fluorescence microscopic images  (A, B) 
and quantification (C, D) of the impact of spermidine on the distribution of GFP-
HDAC4 in HeLa (A, C) or wild-type MEF (B, D) cells are shown. (E, F) Spermidine 
suppresses cytosolic HDAC4. Representative immunoblot results (E) and quantification 
(F) show the impact of spermidine on the distribution of HDAC4 in subcellular fractions 
of HeLa cells. 
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Figure 24. Continued. 
As reported previously (128), phosphorylated HDAC4 binds with 14-3-3 and is 
retained in the cytoplasm; dephosphorylation of HDAC4 on serine 246 and serine 632 is 
important for HDAC4 nuclear import. Thus, levels of phosphorylated HDAC4 were first 
examined to understand the nuclear translocation of HDAC4 after spermidine treatment. 
Decreased levels of phospho-HDAC4 (S246/S632), as well as HDAC4 binding partner 
14-3-3, were observed in cells treated with spermidine (Figure 25A, B). In addition, 
immunoprecipitation results showed that spermidine reduced the association of HDAC4 
with 14-3-3 (Figure 25C, D), which confirmed that HDAC4 was released by 14-3-3 and 
imported to nucleus. 
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Figure 25. Spermidine Dephosphorylates HDAC4 and Induces the Dissociation of 
HDAC4 from 14-3-3. (A, B) Spermidine dephosphorylates HDAC4. Representative 
immunoblot results (A) and quantification (B) of the impact of spermidine on levels of 
total HDAC4, phosphorylated HDAC4, and 14-3-3. (C, D) Spermidine induces the 
dissociation of HDAC4 from 14-3-3. Lysates of HeLa cells untreated or treated with 
spermidine were precipitated with HDAC4 antibodies or IgG control. Representative 
immunoblot results (C) and quantification (D) are shown. 
Spermidine Reduces the Interaction between HDAC4 and MAP1S 
To study the impact of spermidine on HDAC4-MAP1S complex, endogenous 
MAP1S was first precipitated by MAP1S-specific antibodies. Reduced level of bound 
HDAC4 was observed after spermidine treatment (Figure 26A, B), which suggested 
spermidine led to the dissociation of MAP1S from HDAC4. The results were further 
confirmed in the 293T cells overexpressed with HDAC4 and MAP1S. Less amount of 
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bounded MAP1S or HDAC4 was pulled down after spermidine treatment with specific 
antibodies against either HDAC4 or MAP1S for immunoprecipitation (Figure 26C, D). 
The co-localization of HDAC4 with MAP1S in the cytoplasm was significantly reduced 
as detected under fluorescence microscope (Figure 26E, F). Thus, spermidine decreases 
the association of HDAC4 with MAP1S, although total amount of HDAC4 is increased. 
Figure 26. Spermidine Interrupts the Association of HDAC4 with MAP1S. (A, B) 
Spermidine induces the dissociation of endogenous HDAC4 from MAP1S. Lysates of 
HeLa cells untreated or treated with spermidine were precipitated with MAP1S-specific 
antibodies or IgG control. Representative immunoblot results (A) and quantification (B) 
are shown. (C, D) Spermidine reduces the interaction between exogenous HDAC4 and 
MAP1S. Lysates of 293T cells transiently overexpressing HDAC4 and MAP1S, treated 
without or with spermidine, were precipitated with HDAC4- (C), MAP1S- (D) specific 
antibodies or the respective IgG control. (E, F) Spermidine induces HDAC4 nuclear 
translocation and its dissociation from MAP1S. Representative fluorescent images (E) 
and quantification (F) show the co-localization between HDAC4 and MAP1S in the 
HeLa cells co-overexpressing HDAC4 and MAP1S untreated or treated with spermidine. 
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Figure 26. Continued. 
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Spermidine-induced Expansion of Mouse Lifespans Depends on MAP1S 
Spermidine has been shown to increase the lifespans of yeast, nematodes and 
flies in an autophagy-dependent fashion (51). MAP1S activates autophagy to suppress 
oxidative stress and sustain the lifespans of mice (4). To study the impact of spermidine  
 
 
Figure 27. Feeding Mice with Spermidine for One Month Enhances Levels of 
MAP1S Protein and Autophagy Activity. (A-C) Feeding mice with spermidine for one 
month enhances levels of MAP1S protein. Wild-type or MAP1S-/- mice were fed with 
drinking water or drinking water containing 3 mM spermidine for 1 month. 
Representative immunoblot results (A) and quantification of the relative levels of 
MAP1S (B) or poly-ubiquitin proteins (C) of liver lysates are shown.  
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in vivo, wild-type or MAP1S-/- mice were fed with drinking water or drinking water 
containing 3 mM spermidine. As expected, feeding mice with spermidine for 1 month 
enhanced levels of MAP1S and autophagy activity as detected by reduced levels of poly-
ubiquitin proteins (Figure 27A-C). 
Wild-type mice that were continuously fed with drinking water containing 
spermidine for 18 months also sustained higher levels of MAP1S compared to wild-type 
mice fed with drinking water (Figure 28A). Furthermore, mice fed with drinking water 
containing spermidine exhibited significantly lower levels of oxidative stress in liver 
tissues than those fed with drinking water (Figure 28B, C).  
As previously reported, deletion of MAP1S caused sinusoidal dilation in liver 
and shortened the median lifespans of mice from 28.0 months (wild-type mice) to 22.4 
months (MAP1S-/- mice) (4). Histological examination revealed that spermidine 
treatment alleviated sinusoidal dilation in wild-type mice but not MAP1S-/- mice (Figure 
29A, B). A 25% increase of median survival time from 26.9 months to 33.3 months was 
observed in wild-type mice fed with drinking water containing spermidine compared to 
wild-type mice fed with drinking water (Figure 29C, D), corresponding to the increase of 
human lifespans from 74.7 years to 92.5 years. Elevated oxidative stress and sinusoidal 
dilation, and reduced median lifespans from 26.9 months to 21.9 months caused by 
MAP1S deletion were not significantly improved by exposure to spermidine (Figure 28B, 
C and 29A-D). Thus, spermidine-induced expansion of lifespans depends on MAP1S. 
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Figure 28. Feeding Mice with Spermidine for Eighteen Months Enhances MAP1S-
mediated Autophagy to Suppress Oxidative Stress. (A) Feeding mice with spermidine 
for eighteen months enhances levels of MAP1S protein. Representative immunoblot 
results show levels of MAP1S and HDAC4 of liver lysates of wild-type or MAP1S-/- 
mice untreated or treated with spermidine for 18 months. Lysates with the same amount 
of total proteins were subjected to immunoblot with antibodies against MAP1S, HDAC4, 
P27, phosphorylated P27 (p-P27), Bcl-2, phosphorylated Bcl-2 (p-Bcl-2), Beclin 1, 
PI3KCIII, ATG4B, ATG5-ATG12, P62, LC3, or β-Actin. (B, C) Spermidine suppresses 
oxidative stress in wild-type mice but not MAP1S-/- mice.  Representative DHE staining 
results (B) and quantification (C) show levels of oxidative stress among the livers from 
wild-type or MAP1S-/- mice untreated or treated with spermidine for 18 months. 
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Figure 29. Spermidine-induced Lifespan Extension Is MAP1S-dependent. (A, B) 
Spermidine reduces sinusoidal dilatation in wild-type mice but not MAP1S-/- mice. 
Representative H&E staining results (A) and qualification (B) show the intensities of 
sinusoidal dilatation among the liver tissues from wild-type or MAP1S-/- mice untreated 
or treated with spermidine for 18 months. (C, D) Spermidine extends lifespans of wild-
type mice but not MAP1S-/- mice. The Kaplan-Meier survival curves (C) show the 
survival time of wild-type or MAP1S-/- mice untreated or treated with spermidine. A 
table (D) summarizes median survival and hazard ratio based on the plots in (C). 
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Spermidine Suppresses Hepatocellular Carcinogenesis through MAP1S 
Previous results showed that MAP1S-/- mice exposed to diethylnitrosamine (DEN) 
developed more and larger foci of hepatocellular carcinomas (HCC) than wild-type mice 
(33). To study the application of spermidine in suppression of tumorigenesis, DEN-
induced HCC mouse model was utilized. Wild-type or MAP1S-/- mice were injected 
with a single dose of DEN on 15-day after birth and examined for tumor development at 
7-month-old. It was confirmed that MAP1S suppressed the development of HCC (Figure 
30A). Wild-type mice fed with drinking water containing spermidine after DEN 
injection exhibited reduced liver weights, liver to body weight ratios, and less surface 
tumors although the body weights were not altered (Figure 30B-E). The typical 
trabecular hepatocarcinomas as displayed by hematoxylin and eosin (H&E) staining 
were dramatically reduced (Figure 30F).  
Spermidine treatment significantly elevated levels of MAP1S protein (Figure 
31A), and suppressed genomic instability as showed byγ-H2AX, the DNA double-
strand breaks marker, in the immunohistochemistry staining. The number of cells 
positively stained with γ-H2AX was significantly decreased in tumor area of wild-type 
mice fed with drinking water containing spermidine (Figure 31B, C). Depletion of 
MAP1S promoted the development of HCC in MAP1S-/- mice while further spermidine 
treatment exhibited no significant reduction in DNA damages and HCC (Figure 30, 31). 
These results indicate that suppressive role of spermidine in the development of HCC 
acts through MAP1S. 
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Figure 30. Spermidine Suppresses Diethylnitrosamine-induced Hepatocellular 
Carcinomas in the Presence of MAP1S. (A) Spermidine suppresses the development 
of DEN-induced hepatocarcinomas in wild-type mice but not MAP1S-/- mice. 
Representative images show liver tissues from DEN-treated wild-type or MAP1S-/- mice 
fed with drinking water (Ctrl) or spermidine-containing water (SPD). (B-E) Plots show 
the body weights (B), the liver weights (C), the ratios of liver weight to body weight (D) 
and the number of surface tumors of mice as described in (A). (F) Spermidine 
suppresses DEN-induced hepatocarcinomas in wild-type mice but not MAP1S-/- mice. 
Representative H&E staining results of liver sections of DEN-treated 7-month-old mice 
as described in (A) are shown. Bars in (F) were 10 µm. 
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Figure 31. Spermidine Enhances Levels of MAP1S to Suppress Genomic Instability 
during Hepatocarcinogenesis. (A) Spermidine enhances levels of MAP1S in liver 
tissues from DEN-treated mice. Representative immunoblot results show levels of 
MAP1S and HDAC4 of liver lysates. Lysates with the same amount of total proteins 
were subjected to immunoblot analyses with antibodies against MAP1S, HDAC4, Beclin 
1, PI3KCIII, ATG4B, ATG5-ATG12, P62, LC3, or GAPDH. (B, C) Spermidine 
decreases levels of γ-H2AX in hepatocarcinomas developed in wild-type mice but not 
MAP1S-/- mice. Representative immunohistochemistry staining results (B) and 
quantification (C) show γ-H2AX in tumor area in liver sections of DEN-treated mice. 
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Discussion 
Spermidine is recently identified as an autophagy inducer to prolong lifespans in 
model systems (51). By inhibiting the enzyme activity of histone acetyltransferases 
(HAT) and reducing the acetylation of histone H3, spermidine induces global gene 
silencing without affecting the transcription of atg genes (53). Acetylproteomic and 
phosphoproteomic analyses also indicate that spermidine regulates the post-translational 
modification of various proteins in the cytoplasm or nucleus respectively through 
(de)acetylation and (de)phosphorylation processes (127,129). Herein, we demonstrate 
that spermidine promotes the nuclear translocation of HDAC4 via dephosphorylation on 
serine 246 and serine 632 of HDAC4, leading to decreased levels of cytosolic HDAC4 
and reduction in the association of HDAC4 with MAP1S. Spermidine specifically 
inhibits the deacetylation of the cytosolic autophagy activator MAP1S to enhance 
autophagic flux. Though the mechanism by which spermidine regulates HDAC4 
dephosphorylation remains unclear so far, protein phosphatase-2A (PP2A) is considered 
to be a potential regulator of spermidine-induced HDAC4 dephosphorylation. PP2A is 
an identified phosphatase that dephosphorylates HDAC4 and regulates HDAC4 nuclear 
import as previously reported (67). Spermidine may induce the dephosphorylation of 
HDAC4 through activation of PP2A (130). Other evidence suggests that suppression of 
LKB1-AMPK dramatically reduces levels of phosphorylated HDAC4 (131). Spermidine 
shows no impact on the phosphorylation of mTOR substrate, so that autophagy initiation 
through the LKB1-AMPK-mTOR pathway is not affected by spermidine (127), which 
implies spermidine may only alter the HDAC4-specific activity of LKB1. 
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Spermidine enhances the acetylation of MAP1S on lysine 520 as indicated in the 
mass spectrometry analyses (127).  Our study shows that lysine 520 residue of MAP1S 
is critical in spermidine-induced autophagy by promoting autophagosome-lysosome 
fusion process. Though lysine 520 is not localized in the HDAC4-binding domain of 
MAP1S, mutation of lysine 520 reduces the interaction between MAP1S and HDAC4. 
Hence, lysine 520 seems to be important in maintaining protein structure in that future 
study may be focused on the function of acetylation on the lysine 520 of MAP1S. 
In addition to extending lifespans in yeast, nematodes and flies, spermidine has 
been reported to reactivate autophagy to ameliorate myopathic defects of collagen-
deficient mice (132). MAP1S-mediated autophagy is positively related to longevity. 
MAP1S activates autophagy to suppress oxidative stress and sustain the lifespans of 
mice. MAP1S deficient mice have defects in autophagy and exhibit dramatically 
shortened lifespans (4). Here, we, for the first time, show that spermidine treatment 
enhances MAP1S-mediated autophagy, leading to significantly extended lifespans of 
wild-type mice. The results indicate that mice fed with drinking water containing 
spermidine have prolonged lifespans than those of the mice fed with drinking water. The 
median survival has increased from 26.9 months to 33.3 months after spermidine 
treatment. Such an extension of lifespans in mice equals an increase of lifespans from 
74.7 years to 92.5 years in humans. Short mouse lifespans are correlated with low levels 
of autophagy activity, high levels of oxidative stress, and high degrees of sinusoidal 
dilatation, as previously reported (4).  Our results discover that long-term of spermidine 
treatment enhances levels of MAP1S protein together with other autophagy-relevant 
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proteins including class III PI3K, ATG4B, ATG5-12, suggesting that spermidine 
regulates multiple autophagy-relevant proteins that coordinately enhance autophagy 
activity. Autophagy defects lead to enhancement of oxidative stress (15). Mice fed with 
drinking water containing spermidine have high levels of autophagy activity and exhibit 
low levels of oxidative stress in the liver tissues than those of the mice fed with drinking 
water. Sinusoidal dilatation is a type of vascular liver lesions that is characterized by 
widening of hepatic capillaries (4,133). It impairs contractile properties of hepatic 
capillaries and associates with inflammatory hepatocellular adenoma which is formerly 
known as telangiectatic focal nodular hyperplasia (134,135). Mice fed with drinking 
water containing spermidine display low levels of sinusoidal dilatation in the liver 
tissues than those of the mice fed with drinking water, suggesting that spermidine 
maintains liver function to prolong lifespans. 
Besides, our study shows that spermidine suppresses hepatocarcinomas in a 
DEN-induced mouse model. After exposure to carcinogen, mice fed with drinking water 
containing spermidine have lower incidence of HCC and develop less malignant tumor 
than those of the mice fed with drinking water. MAP1S-mediated autophagy removes 
aggresomes that induce oxidative stress and trigger genomic instability. MAP1S 
deficient mice have autophagy defects and develop more malignant tumor in DEN-
induced mouse model, which suggests the importance of MAP1S in tumor suppression 
(33). Long-term feeding of spermidine in DEN-treated mice significantly enhances 
levels of MAP1S protein other than class III PI3K, ATG4B, and ATG5-12, which is 
different from the results in the longevity study. This points out the unique role of 
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MAP1S-mediated autophagy in tumor suppression. Currently, most HCC patients are 
diagnosed at late-stage. Thus, it is important to explore the effect of spermidine on 
advanced HCC as well as HCC prevention in the further study. Since spermidine is a 
natural product plentiful in various kinds of food, consuming spermidine via regular diet 
or supplements may provide a novel paradigm to prevent or treat HCC in a safe and 
cost-effective way.  
Notably, all the impacts of spermidine on lifespan extension and HCC 
suppression depend on the presence of MAP1S, and are abolished in the MAP1S 
deficient mice. Although other biological function of spermidine may exist, the major 
role of spermidine in longevity and tumor suppression is mediated by MAP1S-mediated 
autophagy. Therefore, activation of MAP1S-mediated autophagy provides a novel 
strategy to enhance longevity and suppress tumorigenesis. 
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CHAPTER V  
CONCLUSIONS  
 
Autophagy is a cellular catabolic machinery to clean up dysfunctional organelles, 
misfolded proteins and aggresomes through lysosome-mediated degradation. Autophagy 
also serves as a major mechanism that maintains homeostasis under cellular stress, 
including nutrient fluctuation, growth factor deprivation, hypoxia, etc. By removing 
damaged and harmful organelles that produce reactive oxygen species (ROS) and 
cytotoxic aggregated proteins, autophagy reduces cellular damage and further protects 
genomic stability. Aging and aging-associated pathologies occur as a result of the 
accumulation of cellular damage. Induction of autophagy is a novel strategy to prolong 
lifespans and suppress aging-associated diseases, such as neurodegenerative diseases and 
cancers. 
Understanding the molecular mechanism of autophagy is essential for discovery 
of new targets to manipulate autophagy activity. As a novel microtubule-associated 
autophagy activator, MAP1S has attracted our attention to explore its molecular detail in 
regulating autophagy. MAP1S can directly enhance autophagy by interacting with 
autophagosome-associated LC3 to promote autophagosome formation and transportation 
along microtubule; and may also indirectly enhance autophagy initiation by sustaining 
levels of Bcl-2 and P27. In this study, we have identified HDAC4 as the upstream 
regulator of MAP1S and determined the mechanism that MAP1S is regulated through 
acetylation and deacetylation process. Acetylation of MAP1S maintains its protein 
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stability. Particularly, acetylation on the lysine 520 residue of MAP1S is critical in 
autophagosome-lysosome fusion process. MAP1S co-localizes with HDAC4 in the 
cytoplasm, and interacts with HDAC4 through an HDAC4-binding domain (HBD) 
which is the overlapping region between the heavy chain (HC) and short chain (SC) of 
MAP1S. HDAC4 negatively regulates MAP1S via deacetylation, leading to the 
destabilization of MAP1S protein. Overexpression of HDAC4 decreases levels of 
MAP1S protein and suppresses MAP1S-mediated autophagy. Inhibition of HDAC4 
enhances levels of MAP1S protein and promotes MAP1S-mediated autophagy.  
Huntington’s disease is caused by the accumulation of toxic mutant Huntingtin 
(mHTT) aggregates that leads to neurodegeneration. Autophagy controls the degradation 
of mHTT aggregates and is one of the potential treatments for the disease. HDAC4 
associates with cytoplasmic mHTT aggregates and is suggested to be a target to 
ameliorate neurodegeneration. In this study, we have elucidated the mechanism by 
which HDAC4 regulates mHTT aggregation and discovered a novel approach to 
alleviate mHTT aggregation. HDAC4 destabilizes MAP1S through direct interaction and 
deacetylation, and further suppresses MAP1S-mediated autophagic clearance of mHTT 
aggregates. Overexpression of HBD blocks the interaction between HDAC4 and MAP1S, 
promotes the stabilization of MAP1S protein and activates MAP1S-mediated autophagic 
turnover of mHTT. In addition to HDAC4 reduction, interruption of the specific 
interaction between HDAC4 and MAP1S is a new therapeutic strategy to degrade 
cytoplasmic mHTT aggregates and treat Huntington’s disease. 
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Spermidine is a polyamine that extends lifespans through autophagy induction in 
multiple organisms. As a natural product highly contained in wheat germ, citrus fruits 
and soybeans, spermidine enhances autophagy activity and may be a potential treatment 
for lifespan extension or tumor suppression. In this study, we have deciphered the 
essential role of MAP1S in spermidine-induced autophagy and explored the suppressive 
impact of spermidine on hepatocellular carcinogenesis. Spermidine induces autophagy 
through a MAP1S-dependent mechanism. By dephosphorylating HDAC4 on serine 246 
and serine 632, spermidine leads to the release of HDAC4 from 14-3-3 and HDAC4 
nuclear localization. Decreased cytosolic level of HDAC4 attenuates the interaction 
between HDAC4 and MAP1S. As MAP1S is dissociated from HDAC4, the acetylation 
of MAP1S is maintained for the stabilization of MAP1S protein. Enhancement in levels 
of MAP1S accelerates autophagosomal formation and autolysosomal degradation. In 
addition, spermidine induces acetylation on lysine 520 residue of MAP1S protein to 
promote autophagosome-lysosome fusion. Long-term treatment of spermidine enhances 
levels of MAP1S protein and autophagy activity to reduce cellular oxidative stress in 
mice. In wild-type mice, spermidine prolongs lifespans with an increment of 6 months in 
median survival time, and suppresses diethylnitrosamine-induced hepatocellular 
carcinomas. Depletion of MAP1S impairs spermidine-induced autophagy, which further 
results in the impact of spermidine on lifespan extension and tumor suppression 
abolished in the MAP1S-/- mice. This study reveals that application of spermidine to 
activate MAP1S-mediated autophagy is a promising strategy to suppress aging and 
hepatocarcinogenesis in human.  
  112 
Overall, our study unravels the mechanism that MAP1S is negatively regulated 
by HDAC4 via deacetylation, and demonstrates the significant impact of activating 
MAP1S-mediated autophagy by HDAC4 inhibition on alleviating Huntington’s diseases 
and suppressing hepatocellular carcinogenesis (Figure 32).  
 
 
Figure 32. Proposed Model of Activation of MAP1S-mediated Autophagy by 
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